

Pl 1216782

REC'D 11 OCT 2004

WIPO

PCT

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

October 07, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/367,089

FILING DATE: March 22, 2002

RELATED PCT APPLICATION NUMBER: PCT/US03/08880

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



W. Montgomery
W. MONTGOMERY
Certifying Officer

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

PATENT APPLICATION SERIAL NO. _____

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

03/28/2002 AAD0F01 00000097 60367089

01 FC:114

160.00 DP

PTO-1556
(5/87)

03-23-02

Customer Number: 000959

H / PRA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Yocum, *et al.*Attorney
Docket No. BGI-152-1

For: Methods and Organisms for Production of B6 Vitamers

Commissioner for Patents
Box Provisional Patent Application
Washington, D.C. 20231Jc879 U.S. PTO
60/367089
03/22/02Jc600 U.S. PTO
03/22/02

60367089-1032202

CERTIFICATION UNDER 37 CFR 1.10

Date of Deposit: March 22, 2002

Mailing Label Number: EL 939 868 587 US

I hereby certify that this Cover Sheet for Filing Provisional Application (37 C.F.R. §1.51(2)(i)) and the documents referred to as attached therein are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and addressed to the Commissioner for Patents, Box Provisional Patent Application, Washington, D.C. 20231.

Larry Taylor

Name of Person Mailing Paper

Larry Taylor

Signature of Person Mailing Paper

COVER SHEET FOR FILING PROVISIONAL PATENT APPLICATION

Dear Sir:

The accompanying application, entitled "Methods and Organisms for Production of B6 Vitamers," is a provisional patent application under 37 C.F.R. §1.51(c) and §1.53(c).

1. ☒ The name(s) and address(es) of the inventor(s) of this application is/are as follows:

1	Yocum	R.	Rogers	4 Orchard Lane, Lexington, Massachusetts 02420
2	Williams	Mark	K.	58 School Street, Revere, Massachusetts 02151
3	Pero	Janice	G.	20 Solomon Pierce Road, Lexington, Massachusetts 02420

2. ☒ The following documents are enclosed:

- ☒ 28 page(s) of Specification
- ☒ 6 page(s) of Claims
- ☒ 1 page(s) of Abstract
- ☒ 12 page(s) of Sequence Listing
- ☒ 7 sheets of Informal Drawings; and
- ☒ Return postcard.

3. ☒ The fee for filing this provisional application, as set forth in 37 CFR 1.16(k), is \$160.00.

- a. ☒ A check for this filing fee is enclosed.
- b. ☐ Charge the filing fee to Deposit Account No. _____
(A duplicate copy of this sheet is enclosed.)
- c. ☐ The filing fee is not being paid at this time.

4. ☒ Please charge any fee deficiencies associated with this filing to Deposit Account No. 12-0080. A duplicate copy of this sheet is enclosed.

5. ☒ Please address all future communications to: **Customer Number: 000959** whose address is:


Lahive & Cockfield, LLP
28 State Street
Boston, MA 02109

and direct telephone calls to: Elizabeth A. Hanley, (617) 227-7400

March 22, 2002
Date

LAHIVE & COCKFIELD, LLP
28 State Street
Boston, MA 02109
Tel. (617) 227-7400

Respectfully submitted,



Debra J. Milasincic, Esq.
Reg. No. 46,931
Attorney for Applicants

150367089.032202

METHODS AND ORGANISMS FOR PRODUCTION OF B6 VITAMERS

Background of the Invention

- 5 Vitamin B6, also known as pyridoxine or pyridoxol (PN), or one of a number of closely related compounds, is an essential dietary nutrient for most, if not all, animals, while many micro-organisms (bacteria, fungi, algae, etc.) and plants are capable of synthesizing their own vitamin B6 or compound(s) related to vitamin B6. When an animal ingests PN or a related compound that has vitamin B6 activity, the
- 10 compound is converted ultimately into pyridoxal phosphate (PLP) and/or pyridoxamine phosphate (PMP), which are the active forms of vitamin B6 in all living organisms. PLP acts as a cofactor for many important or essential enzymes in all living organisms, including transaminases, racemases, and decarboxylases. PLP and PMP are easily interconverted by ubiquitous transaminases.
- 15 Vitamin B6 is of commercial importance in vitamin pills, pharmaceutical applications, and as an animal feed additive that enhances growth or desirable growth characteristics in farm and domestic animals. The currently used commercial process for producing vitamin B6 is a synthetic chemical process. However, a fermentation process using a microorganism (see US Patent application No. 09/667,569, filed
- 20 September 21, 2000, hereby incorporated in its entirety by reference) or a biosynthetic process using a plant species can be more cost effective in the long run, and may be environmentally more attractive.
- The biosynthetic pathway for PLP in *E. coli* has been elucidated (reviewed in Mittengruber, G., (2001) *J. Mol. Microbiol. Biotechnol.* 3(1): 1-20; Cane, D.E., et al. (2000) *J. Am. Chem. Soc.* 122: 4213-4214; Man, T-K, et al., (1996) *J. Bacteriol.* 178: 2445-2449). Enzymes encoded by the genes *epd*, *pdxB*, *pdxF*, and *pdxA* lead to synthesis of the precursor 1-hydroxy-3-amino acetone phosphate from erythrose-4-phosphate and glutamate. The enzyme encoded by *dxs* leads to the precursor 5'-deoxyxylulose phosphate from glycolytic intermediates. The enzyme encoded by *pdxJ*
- 30 then catalyzes the chemical coupling of the two precursors to give pyridoxol phosphate (also called pyridoxine phosphate or PNP). PNP is then oxidized to the active form, PLP, by the enzyme encoded by *pdxH*. This biosynthetic pathway to PLP in *E. coli*, as well as closely related pathways, are referred to herein as the Type A Pathway. Partially characterized mutants of *E. coli* have been described that produce about three- to seven-
- 35 fold more vitamin B6-related compounds than the parent strain (Dempsey and Arcement (1971) *J. Bacteriol.* 107(2): 580-582). Partially characterized mutants of *B. subtilis* have been reported that produce 1 - 5 mg/l vitamin B6, but it was not stated what level the

150367089-032202

parent strain produced (Pflug, W., and Lingens, F., (1978) Hoppe-Seyler's Z. Physiol. Chem. 359: 559-570). Notably, these organisms were not recombinantly produced.

- A second biosynthetic pathway for vitamin B6, referred to herein as the Type B pathway, may exist in some organisms other than *E. coli* (Mittengruber, G., (2001) *J. Mol. Microbiol. Biotechnol.* 3(1):1-20). In particular, some fungi (for example from the genera *Cercospora*, *Neurospora*, *Aspergillus* and *Saccharomyces*), some bacteria (for example *B. subtilis* and *Staphylococcus aureus*), and all plants for which data exists do not contain any genes that are highly homologous to *E. coli* *pdxA* and *pdxJ*. Instead, these organisms contain genes that are homologous to *Cercospora* genes named *SOR* (or *SNZ*) and *SNO*. In *Saccharomyces*, these homologs are called *PDX1* and *PDX2*, respectively, and in *B. subtilis*, these homologs are named *yaaD* and *yaaE*, respectively. In *B. subtilis*, there have been no reports as to whether *yaaD* or *yaaE* are actually involved in PLP biosynthesis. Protein or DNA sequence homology alone is not sufficient to establish biological function. For example, *B. subtilis* contains a gene, *yhaF*, that encodes a protein that is significantly homologous to *E. coli* *pdxF*. However, when *yhaF* is mutated, the resulting mutant *B. subtilis* strain is a serine auxotroph, but not a PL auxotroph (see Example 3, below). Thus, the identification of a gene or genes involved in PLP biosynthesis in any given organism can not be done using sequence homology alone.
- Results from ¹³C and ¹⁵N labeling studies suggest that the precursors that provide the carbon and nitrogen atoms in PL and related compounds are different in *E. coli* and *Saccharomyces cerevisiae* (Gupta, R., et al. (2001) *J. Am Chem. Soc.* 123: 11353-11359; Tayuza, K., et al. (1995) *Biochim. Biophys. Acta* 1244: 113-116.) However, the identity of the precursors for PL and related compounds in *S. cerevisiae* is not yet known. Since most micro-organisms for which the entire genome sequence is known (for example *E. coli*, *S. cerevisiae* and *B. subtilis*) have either *pdxA* and *pdxJ* homologs or *SOR* and *SNO* homologs, but not both, it appears that most organisms that are capable of synthesizing PLP have either the well characterized Type A Pathway (for example *E. coli*, *Salmonella typhimurium*, and many other genera), or a distinctly different and incompletely characterized pathway, e.g., the Type B Pathway. Specifically, members of the genera *Cercospora*, *Neurospora*, *Aspergillus*, *Saccharomyces*, *Bacillus*, *Arabidopsis*, and many other genera, appear to have a Type B pathway, and are lacking genes involved in the Type A Pathway. The intermediate compounds in the Type B Pathway have not yet been elucidated, although the final product must be PLP (as for the Type A Pathway) or PMP, since these are the active forms of vitamin B6 in all known organisms.

60367089-032202

Summary of the Invention

The present invention is based, at least in part, on the discovery of key enzyme-encoding genes of the B6 vitamer biosynthetic pathways in *Bacillus subtilis*. In particular, the invention is based, at least in part, on the discovery that the *yaaD* and *yaaE* genes of *B. subtilis* are required for B6 vitamer synthesis. Deletion of a portion of the *yaaD* and *yaaE* genes (which are adjacent in an operon, *e.g.*, the *yaaDE* operon) leads to PL auxotrophy. Overexpression of the *yaaDE* operon or the deregulation of the expression of the *yaaD* or *yaaE* genes leads to significantly increased production of B6 vitamers in, *e.g.*, *B. subtilis* strains. The *B. subtilis yaaDE* operon is required for pyridoxal phosphate (PLP) biosynthesis, an active form of vitamin B6 in all living organisms. The present invention describes that the expression of the *B. subtilis yaaDE* operon is a rate limiting step for production of compounds related to vitamin B6 in a wild type strain.

Accordingly, the present invention features methods of producing B6 vitamers, including, but not limited to, pyridoxine (or pyridoxol (PN)), pyridoxal (PL); pyridoxamine (PM), or the 5' phosphorylated derivatives of any of the three aforementioned compounds (PNP, PLP, and PMP), using organisms in which the B6 vitamer pathway has been manipulated such that B6 vitamers are produced. Such methods include culturing a microorganism that overexpresses at least one B6 vitamer biosynthetic enzyme (*e.g.*, at least one of the *yaaD* or *yaaE* gene products), under conditions such that the B6 vitamer is produced. The production methods of the present invention further can include recovering the B6 vitamer.

The instant invention also features genetically modified organisms (*i.e.*, organisms that contain one or more modifications or mutations in the genome) that are capable of producing significantly more of a B6 vitamer than an unmodified parent organism. In particular, this invention features micro-organisms (including, for example, but not limited to, bacteria, yeasts, fungi, and algae) or macro-organisms such as plants that, when genetically modified, produce an increased amount, *e.g.*, at least about 10-fold more of a B6 vitamer, than the unmodified parent organism. Specific examples are given herein in which *Bacillus subtilis* and *Escherichia coli* strains have been genetically modified such that they produce significant amounts of a B6 vitamer. Accordingly, the present invention features organisms that have been genetically modified to increase the activity of one or more enzymes that catalyze(s) a step in the biosynthesis of a B6 vitamer, such that B6 vitamer production from said modified organism is increased compared to B6 production in an unmodified parent organism.

Yet another aspect of the invention features recombinant microorganisms which overexpress at least one *Bacillus* (*e.g.*, *B. subtilis*) B6 vitamer biosynthetic

60367089.032202

enzyme (e.g., at least one of the *yaaD* or *yaaE* gene products) are described. In one embodiment, the recombinant microorganism is Gram positive (e.g., microorganisms belonging to the genus *Bacillus*, *Corynebacterium*, *Lactobacillus*, *Lactococci* or *Streptomyces*). In another embodiment, the recombinant microorganism is Gram negative. Particularly preferred is a *Bacillus* recombinant microorganism (e.g., *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, *Bacillus pumilus*, *Bacillus halodurans*, and the like).

Recombinant vectors that contain genes encoding *Bacillus* B6 vitamer biosynthetic enzymes, e.g., *yaaD* or *yaaE* genes, are also described.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

Brief Description of the Drawings

Figure 1 depicts the chemical structures of vitamin B6 and related compounds.

Figure 2 depicts the biosynthetic pathway for PLP in *E. coli*.

Figure 3 depicts the standard curves generated by *Saccharomyces unarum* strain ATCC 9080 after feeding serial dilutions of PN, PL, and PM (as described in Example 1).

Figure 4 is a schematic representation of the plasmid pDX1F.

Figure 5 is a schematic representation of the plasmid pDX11F.

Figure 6 is a schematic representation of the plasmid pDX14R.

Figure 7 is a schematic representation of the plasmid pDX17R.

Detailed Description of the Invention

The present invention is based, at least in part, on the identification of *Bacillus* (e.g., *B. subtilis*) genes that encode essential enzymes of the B6 vitamer biosynthetic pathway. In particular, the present invention features methods based on manipulation of the B6 vitamer biosynthetic pathway in a microorganism such that certain desirable compounds are produced.

In particular, the invention is based, at least in part, on the discovery that the *yaaD* and *yaaE* genes of *B. subtilis* are required for B6 vitamer synthesis, including, but not limited to, pyridoxine (or pyridoxol (PN)), pyridoxal (PL), pyridoxamine (PM), or the 5' phosphorylated derivatives of any of the three aforementioned compounds (PNP, PLP, and PMP). The *yaaD* and *yaaE* genes are adjacent on an operon, e.g., the *yaaDE* operon. The *yaaD* and *yaaE* genes encode the YaaD and Yaa E proteins,

respectively. Overexpression of the *yaaDE* operon with a strong constitutive promoter or the deregulation of the expression of the *yaaD* or *yaaE* gene(s) leads to significantly increased production of B6 vitamers. These quantities are significantly higher relative to the associated parent strains than those reported in previous studies, which have
5 employed mutant *E. coli* strains (Dempsey and Arcement (1971) *J. Bacteriol.* 107 (2): 580-582), or mutant *B. subtilis* strains (Pflug, W., and Lingens, F., (1978) Hoppe-Seyler's Z. Physiol. Chem. 359: 559-570).

Accordingly, the present invention features organisms that have been genetically modified to increase the activity of one or more enzymes that catalyze a step
10 in the biosynthesis of a B6 vitamer, such that B6 vitamer production from the modified organism is increased compared to B6 production in an unmodified parent organism. In one embodiment, B6 vitamer production is at least ten-fold higher than from the unmodified parent organism. In another embodiment, the organism is genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step
15 in the biosynthesis of a B6 vitamer, *e.g.*, *yaaD* or *yaaE*. The organism may be, for example, *B. subtilis*.

The present invention also features methods of producing a B6 vitamer comprising culturing a microorganism that has been genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step in the biosynthesis of a
20 B6 vitamer, such that B6 vitamer production from said modified organism is increased compared to B6 production in an unmodified parent organism, under conditions such that the B6 vitamer is produced. The B6 vitamer may then be subsequently recovered. Overproduction of the rate limiting enzyme for B6 vitamer production in any organism that is capable of producing B6 vitamers will lead to overproduction of B6 vitamers.

25 The terms "B6 vitamer" or "B6 vitamers," as used herein, shall refer to any compound or mixture of compounds that has any biological activity in any biological assay for vitamin B6. B6 vitamers include, but are not limited to, pyridoxine (also called pyridoxol or PN), pyridoxal (PL), pyridoxamine (PM), the 5' phosphorylated derivatives of any of the three aforementioned compounds (PNP, PLP, and PMP), and any derivative or related compound that can be converted to the active
30 forms (PLP or PMP) in a test organism. Thus, for example, the acetate esters or other esters of any of the available hydroxyl groups of any of the aforementioned six compounds, and which are likely to be hydrolyzed by specific or non-specific esterases, are included in B₆ vitamers. Also, various salts, such as hydrochloride salts, of any of
35 the aforementioned compounds are included in B6 vitamers.

The term "B6 vitamer biosynthetic pathway" includes the biosynthetic pathway involving B6 vitamer biosynthetic enzymes (*e.g.*, polypeptides encoded by

60367089-032202

biosynthetic enzyme-encoding genes), compounds (*e.g.*, precursors, substrates, intermediates or products), cofactors and the like utilized in the formation or synthesis of B6 vitamers. The term "B6 vitamer biosynthetic pathway" includes the biosynthetic pathway leading to the synthesis of B6 vitamers in a microorganism (*e.g.*, *in vivo*) as well as the biosynthetic pathway leading to the synthesis of B6 vitamers *in vitro*.

A "biological assay for a B6 vitamer" includes, for example, any assay that is capable of quantifying B6 vitamer activity by measuring growth of an organism that requires the feeding of a B6 vitamer (*i.e.*, a compound that the fed organism can convert into PLP or PMP) for growth. Samples to be assayed are diluted serially in an appropriate medium and fed to the appropriate organism. Standard curves are generated by serially diluting known amounts of PL, PN, or PM, and feeding these dilutions to the test organism. By comparing dilutions of the unknown samples to the standard curves, total B6 vitamer activity can be determined, for example as PL equivalents if PL was used to generate the standard curve.

Various aspects of the invention are described in further detail in the following subsections.

I. Genes Encoding Various B6 Vitamer Biosynthetic Enzymes

In one embodiment, the present invention features targeting or modifying various biosynthetic genes or enzymes of the B6 vitamer biosynthetic pathway. In particular, the invention features modifying various enzymatic activities associated with said pathways by modifying or altering the genes encoding said biosynthetic enzymes.

The term "gene", as used herein, includes a nucleic acid molecule (*e.g.*, a DNA molecule or segment thereof) that, in an organism, can be separated from another gene or other genes, by intergenic DNA (*i.e.*, intervening or spacer DNA which naturally flanks the gene and/or separates genes in the chromosomal DNA of the organism). Alternatively, a gene may slightly overlap another gene (*e.g.*, the 3' end of a first gene overlapping the 5' end of a second gene), said overlapping genes separated from other genes by intergenic DNA. A gene may direct synthesis of an enzyme or other protein molecule (*e.g.*, may comprise coding sequences, for example, a contiguous open reading frame (ORF) which encodes a protein) or may itself be functional in the organism. A gene in an organism, may be clustered in an operon, as defined herein, said operon being separated from other genes and/or operons by the intergenic DNA. An "isolated gene", as used herein, includes a gene which is essentially free of sequences which naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived (*i.e.*, is free of adjacent coding sequences which encode a second or

50367039.032202

distinct protein, adjacent structural sequences or the like) and optionally includes 5' and 3' regulatory sequences, for example promoter sequences and/or terminator sequences. In one embodiment, an isolated gene includes predominantly coding sequences for a protein (*e.g.*, sequences which encode *Bacillus* proteins). In another embodiment, an isolated gene includes coding sequences for a protein (*e.g.*, for a *Bacillus* protein) and adjacent 5' and/or 3' regulatory sequences from the chromosomal DNA of the organism from which the gene is derived (*e.g.*, adjacent 5' and/or 3' *Bacillus* regulatory sequences). Preferably, an isolated gene contains less than about 10 kb, 5 kb, 2 kb, 1 kb, 0.5 kb, 0.2 kb, 0.1 kb, 50 bp, 25 bp or 10 bp of nucleotide sequences that naturally flank the gene in the chromosomal DNA of the organism from which the gene is derived.

The term "operon" includes at least two adjacent genes or ORFs, optionally overlapping in sequence at either the 5' or 3' end of at least one gene or ORF. The term "operon" includes a coordinated unit of gene expression that contains a promoter and possibly a regulatory element associated with one or more adjacent genes or ORFs (*e.g.*, structural genes encoding enzymes, for example, biosynthetic enzymes). Expression of the genes (*e.g.*, structural genes) can be coordinately regulated, for example, by regulatory proteins binding to the regulatory element or by anti-termination of transcription. The genes of an operon (*e.g.*, structural genes) can be transcribed to give a single mRNA that encodes all of the proteins.

A "gene having a mutation" or "mutant gene" as used herein, includes a gene having a nucleotide sequence which includes at least one alteration (*e.g.*, substitution, insertion, deletion) such that the polypeptide or protein encoded by said mutant exhibits an activity that differs from the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. In one embodiment, a gene having a mutation or mutant gene encodes a polypeptide or protein having an increased activity as compared to the polypeptide or protein encoded by the wild-type gene, for example, when assayed under similar conditions (*e.g.*, assayed in microorganisms cultured at the same temperature). As used herein, an "increased activity" or "increased enzymatic activity" is one that is at least 5% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% greater, more preferably at least 10-25% greater and even more preferably at least 25-50%, 50-75% or 75-100% greater than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, *e.g.*, 75-85%, 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, an "increased activity" or "increased enzymatic activity" can also include an activity that is at least 1.25-fold greater than the activity of the polypeptide or protein encoded by the wild-type gene, preferably at least 1.5-fold

60367089-032202

greater, more preferably at least 2-fold greater and even more preferably at least 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold or greater than the activity of the polypeptide or protein encoded by the wild-type gene.

- In another embodiment, a gene having a mutation or mutant gene
- 5 encodes a polypeptide or protein having a reduced activity as compared to the polypeptide or protein encoded by the wild-type gene, for example, when assayed under similar conditions (e.g., assayed in microorganisms cultured at the same temperature). A mutant gene also can encode no polypeptide or have a reduced level of production of the wild-type polypeptide. As used herein, a "reduced activity" or "reduced enzymatic
- 10 activity" is one that is at least 5% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene, preferably at least 5-10% less, more preferably at least 10-25% less and even more preferably at least 25-50%, 50-75% or 75-100% less than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene. Ranges intermediate to the above-recited values, e.g., 75-85%,
- 15 85-90%, 90-95%, are also intended to be encompassed by the present invention. As used herein, a "reduced activity" or "reduced enzymatic activity" can also include an activity that has been deleted or "knocked out" (e.g., approximately 100% less activity than that of the polypeptide or protein encoded by the wild-type nucleic acid molecule or gene).
- 20 Activity can be determined according to any well accepted assay for measuring activity of a particular protein of interest. Activity can be measured or assayed directly, for example, measuring an enzymatic or biological activity of a protein isolated or purified from a cell or microorganism. Alternatively, an activity can be measured or assayed within a cell or microorganism or in an extracellular medium. For
- 25 example, assaying for a mutant gene (i.e., said mutant encoding a reduced enzymatic activity) can be accomplished by expressing the mutated gene in a microorganism, for example, a mutant microorganism in which the enzyme is temperature-sensitive, and assaying the mutant gene for the ability to complement a temperature sensitive (Ts) mutant for enzymatic activity. A mutant gene that encodes an "increased enzymatic
- 30 activity" can be one that complements the Ts mutant more effectively than, for example, a corresponding wild-type gene. A mutant gene that encodes a "reduced enzymatic activity" is one that complements the Ts mutant less effectively than, for example, a corresponding wild-type gene.

- It will be appreciated by the skilled artisan that even a single substitution
- 35 in a nucleic acid or gene sequence (e.g., a base substitution that encodes an amino acid change in the corresponding amino acid sequence) can dramatically affect the activity of an encoded polypeptide or protein as compared to the corresponding wild-type

E0367089-032202

polypeptide or protein. A mutant gene (e.g., encoding a mutant polypeptide or protein), as defined herein, is readily distinguishable from a nucleic acid or gene encoding a protein homologue in that a mutant gene encodes a protein or polypeptide having an altered activity, optionally observable as a different or distinct phenotype in a

5 microorganism expressing said mutant gene or producing said mutant protein or polypeptide (i.e., a mutant microorganism) as compared to a corresponding microorganism expressing the wild-type gene. By contrast, a protein homologue has an identical or substantially similar activity, optionally phenotypically indiscernible when produced in a microorganism, as compared to a corresponding microorganism

10 expressing the wild-type gene. Accordingly it is not, for example, the degree of sequence identity between nucleic acid molecules, genes, protein or polypeptides that serves to distinguish between homologues and mutants, rather it is the activity of the encoded protein or polypeptide that distinguishes between homologues and mutants: homologues having, for example, low (e.g., 30-50% sequence identity) sequence

15 identity yet having substantially equivalent functional activities, and mutants, for example sharing 99% sequence identity yet having dramatically different or altered functional activities.

60367089.032202

In a preferred embodiment, the genes of the present invention are derived from *Bacillus*. The term "derived from *Bacillus*" or "*Bacillus*-derived" includes a gene

20 which is naturally found in microorganisms of the genus *Bacillus*. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group consisting of *Bacillus subtilis*, *Bacillus lentimorbus*, *Bacillus lentus*, *Bacillus firmus*, *Bacillus pantothenicus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus licheniformis*, *Bacillus*

25 *megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other Group 1 *Bacillus* species, for example, as characterized by 16S rRNA type. In another preferred embodiment, the gene is derived from *Bacillus brevis* or *Bacillus stearothermophilus*. In another preferred embodiment, the genes of the present invention are derived from a microorganism selected from the group consisting of

30 *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*. In a particularly preferred embodiment, the gene is derived from *Bacillus subtilis* (e.g., is *Bacillus subtilis*-derived). The term "derived from *Bacillus subtilis*" or "*Bacillus subtilis*-derived" includes a gene which is naturally found in the microorganism *Bacillus subtilis*. Included within the scope of the present invention are

35 *Bacillus*-derived genes (e.g., *B. subtilis*-derived genes), for example, *Bacillus* or *B. subtilis yaaD* or *yaaE* genes.

II. Recombinant Nucleic Acid Molecules and Vectors

The present invention further features recombinant nucleic acid molecules (e.g., recombinant DNA molecules) that include genes described herein (e.g., isolated genes), preferably *Bacillus* genes, more preferably *Bacillus subtilis* genes, even more preferably *Bacillus subtilis* B6 vitamer biosynthetic genes. The term "recombinant nucleic acid molecule" includes an isolated nucleic acid molecule (e.g., a DNA molecule) that has been altered, modified or engineered such that it differs in nucleotide sequence from the native or natural nucleic acid molecule from which the recombinant nucleic acid molecule was derived (e.g., by addition, deletion or substitution of one or more nucleotides). Preferably, a recombinant nucleic acid molecule (e.g., a recombinant DNA molecule) includes an isolated gene of the present invention operably linked to regulatory sequences. The phrase "operably linked to regulatory sequence(s)" means that the nucleotide sequence of the gene of interest is linked to the regulatory sequence(s) in a manner which allows for expression (e.g., enhanced, increased, constitutive, basal, attenuated, decreased or repressed expression) of the gene, preferably expression of a gene product encoded by the gene (e.g., when the recombinant nucleic acid molecule is included in a recombinant vector, as defined herein, and is introduced into a microorganism). A "recombinant organism" is any organism that contains a recombinant nucleic acid molecule.

The term "regulatory sequence" includes nucleic acid sequences that affect (e.g., modulate or regulate) expression of other nucleic acid sequences (i.e., genes). In one embodiment, a regulatory sequence is included in a recombinant nucleic acid molecule in a similar or identical position and/or orientation relative to a particular gene of interest as is observed for the regulatory sequence and gene of interest as it appears in nature, e.g., in a native position and/or orientation. For example, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to the gene of interest in the natural organism (e.g., operably linked to "native" regulatory sequences (e.g., to the "native" promoter). Alternatively, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence which accompanies or is adjacent to another (e.g., a different) gene in the natural organism. Alternatively, a gene of interest can be included in a recombinant nucleic acid molecule operably linked to a regulatory sequence from another organism. For example, regulatory sequences from other microbes (e.g., other bacterial regulatory sequences, bacteriophage regulatory sequences and the like) can be operably linked to a particular gene of interest.

In one embodiment, a regulatory sequence is a non-native or non-naturally-occurring sequence (e.g., a sequence which has been modified, mutated,

60367089.032202

- substituted, derivatized, deleted including sequences which are chemically synthesized). Preferred regulatory sequences include promoters, enhancers, termination signals, anti-termination signals, ribosome binding sites and other expression control elements (e.g., sequences to which repressors or inducers bind and/or binding sites for transcriptional and/or translational regulatory proteins, for example, in the transcribed mRNA). Such regulatory sequences are described, for example, in Sambrook, J., Fritsh, E. F., and Maniatis, T. *Molecular Cloning: A Laboratory Manual*. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in a microorganism (e.g., constitutive promoters and strong constitutive promoters), those which direct inducible expression of a nucleotide sequence in a microorganism (e.g., inducible promoters, for example, xylose inducible promoters) and those which attenuate or repress expression of a nucleotide sequence in a microorganism (e.g., attenuation signals or repressor sequences). It is also within the scope of the present invention to regulate expression of a gene of interest by removing or deleting regulatory sequences. For example, sequences involved in the negative regulation of transcription can be removed such that expression of a gene of interest is enhanced.

- In one embodiment, a recombinant nucleic acid molecule of the present invention includes a nucleic acid sequence or gene that encodes at least one bacterial gene product (e.g., a B6 vitamers biosynthetic enzyme, e.g., the gene product of *yaaD* and/or *yaaE*) operably linked to a promoter or promoter sequence. Preferred promoters of the present invention include *Bacillus* promoters and/or bacteriophage promoters (e.g., bacteriophage which infect *Bacillus*). In one embodiment, a promoter is a *Bacillus* promoter, preferably a strong *Bacillus* promoter (e.g., a promoter associated with a biochemical housekeeping gene in *Bacillus* or a promoter associated with a glycolytic pathway gene in *Bacillus*). In another embodiment, a promoter is a bacteriophage promoter. In a preferred embodiment, the promoter is from the bacteriophage SP01. In a particularly preferred embodiment, a promoter is selected from the group consisting of *P₁₅*, *P₂₆*, or *P_{veg}* having for example, the following respective sequences:
- 30 GCTATTGACGACAGCTATGGTTCACTGTCCACCAACCAAACTGTGCTCAGT
ACCGCCAATATTTCTCCCTTGAGGGGTACAAAGAGGTGTCCCTAGAAGAGAT
CCACGCTGTGTAAAAATTTACAAAAAGGTATTGACTTTCCCTACAGGGTGT
GTAATAATTTAATTACAGGCGGGGGCAACCCGCCTGT (SEQ ID NO:9),
GCCTACCTAGCTTCCAAGAAAGATATCCTAACAGCACAAGAGCGGAAAGAT
35 GTTTTGTCTACATCCAGAACAACCTCTGCTAAAATTCCTGAAAAATTTTGC
AAAAAGTTGTTGACTTTATCTACAAGGTGTGGTATAATAATCTTAACAACAG
CAGGACGC (SEQ ID NO:10); and

0367089-032202

GAGGAATCATAGAATTTTGTCAAAATAATTTTATTGACAACGTCTTATTAAC
 GTTGATATAATTTAAATTTTATTTGACAAAAATGGGCTCGTGTTGTACAATA
 AATGTAGTGAGGTGGATGCAATG (SEQ ID NO:11). Additional preferred
 promoters include *tef* (the translational elongation factor (TEF) promoter) and *pyc* (the
 5 pyruvate carboxylase (PYC) promoter), which promote high level expression in *Bacillus*
 (e.g., *Bacillus subtilis*). Additional preferred promoters, for example, for use in Gram
 positive microorganisms include, but are not limited to, *amy* and SPO2 promoters.
 Additional preferred promoters, for example, for use in Gram negative microorganisms
 include, but are not limited to, *tac*, *trp*, *tet*, *trp-tet*, *lpp*, *lac*, *lpp-lac*, *lacIQ*, T7, T5, T3,
 10 *gal*, *trc*, *ara*, SP6, λ -PR or λ -PL.

In another embodiment, a recombinant nucleic acid molecule of the
 present invention includes a terminator sequence or terminator sequences (e.g.,
 transcription terminator sequences). The term "terminator sequences" includes
 regulatory sequences that serve to terminate transcription of mRNA. Terminator
 15 sequences (or tandem transcription terminators) can further serve to stabilize mRNA
 (e.g., by adding structure to mRNA), for example, against nucleases.

In yet another embodiment, a recombinant nucleic acid molecule of the
 present invention includes sequences which allow for detection of the vector containing
 said sequences (i.e., detectable and/or selectable markers), for example, genes that
 20 encode antibiotic resistance or sequences that overcome auxotrophic mutations, for
 example, *trpC*, fluorescent markers, drug markers, and/or colorimetric markers (e.g.,
lacZ/ β -galactosidase). In yet another embodiment, a recombinant nucleic acid molecule
 of the present invention includes an artificial ribosome binding site (RBS) or a sequence
 that becomes transcribed into an artificial RBS. The term "artificial ribosome binding
 25 site (RBS)" includes a site within an mRNA molecule (e.g., coded within DNA) to
 which a ribosome binds (e.g., to initiate translation) which differs from a native RBS
 (e.g., a RBS found in a naturally-occurring gene) by at least one nucleotide. Preferred
 artificial RBSs include about 5-6, 7-8, 9-10, 11-12, 13-14, 15-16, 17-18, 19-20, 21-22,
 23-24, 25-26, 27-28, 29-30 or more nucleotides of which about 1-2, 3-4, 5-6, 7-8, 9-10,
 30 11-12, 13-15 or more differ from the native RBS (e.g., the native RBS of a gene of
 interest, for example, the native *yaaD* RBS

GAAATCATATAACTATACCTTGATTAGGGGGACCAAGAAATG
 (SEQ ID NO:12) or the native *yaaE* RBS
 CAAGAACGCGCTGGTAAGAACATAGGAGCGCTGCTGACATG (SEQ ID
 35 NO:13)).

Preferably, nucleotides that differ are substituted such that they are
 identical to one or more nucleotides of an ideal RBS when optimally aligned for

60367089-032202

comparisons. Artificial RBSs can be used to replace the naturally-occurring or native RBSs associated with a particular gene. Artificial RBSs preferably increase translation of a particular gene. Preferred artificial RBSs (*e.g.*, RBSs for increasing the translation of *yaaE*, for example, of *B. subtilis*) are set forth in Table 1, below.

5

Table 1: Preferred Ribosome Binding Sites

		10	20	
		<hr/>		
				SEQ ID NO:
10	Native_yaaD	---GAAATCATATAACTATACCTTGATTAGGGGGACC--AAGAAATG		12
	Native_yaaE	CAAGAACGCGGCTGGTAAGAACAT----AGGAGCGCTGCTGACATG		13
	IDEAL_RBS	-----TCTAGAAAGG-----AGGTG-----A-----		14
	RBS1	-----TCTAGAAAGG-----AGGAG-----AAAACATG		15
15	RBS2	-----TCTAGAGG-----AGGAG-----AAAACATG		16
	RBS101	-----TAAGAACAA-----AGGAGGAGAGCTGACATG		17
	RBS103	-----TAAGAAGAA-----AGGAGGTGAGCTGACATG		18
	RBS102	-----TAAGAACAG-----AGGAGGAGAGCTGACATG		19

20 The present invention further features vectors (*e.g.*, recombinant vectors) that include nucleic acid molecules (*e.g.*, genes or recombinant nucleic acid molecules comprising said genes) as described herein. The term "recombinant vector" includes a vector (*e.g.*, plasmid, phage, phasid, virus, cosmid or other purified nucleic acid vector) that has been altered, modified or engineered such that it contains greater, fewer

25 or different nucleic acid sequences than those included in the native or natural nucleic acid molecule from which the recombinant vector was derived. Preferably, the recombinant vector includes a biosynthetic enzyme-encoding gene or recombinant nucleic acid molecule including said gene, operably linked to regulatory sequences, for example, promoter sequences, terminator sequences and/or artificial ribosome binding

30 sites (RBSs), as defined herein. In another embodiment, a recombinant vector of the present invention includes sequences that enhance replication in bacteria (*e.g.*, replication-enhancing sequences). In one embodiment, replication-enhancing sequences are derived from *E. coli*. In another embodiment, replication-enhancing sequences are derived from pBR322. In another embodiment, replication-enhancing sequences are

35 derived from pSC101.

In yet another embodiment, a recombinant vector of the present invention includes antibiotic resistance sequences. The term "antibiotic resistance sequences" includes sequences which promote or confer resistance to antibiotics on the host organism (*e.g.*, *Bacillus*). In one embodiment, the antibiotic resistance sequences are

40 selected from the group consisting of *cat* (chloramphenicol resistance) sequences, *tet* (tetracycline resistance) sequences, *erm* (erythromycin resistance) sequences, *neo*

60367089-032202

(neomycin resistance) sequences, *kan* (kanamycin resistance) and *spec* (spectinomycin resistance) sequences. Recombinant vectors of the present invention can further include homologous recombination sequences (e.g., sequences designed to allow recombination of the gene of interest into the chromosome of the host organism). For example, *bpr*, *vpr*, and/or *amyE* sequences can be used as homology targets for recombination into the host chromosome. It will further be appreciated by one of skill in the art that the design of a vector can be tailored depending on such factors as the choice of microorganism to be genetically engineered, the level of expression of gene product desired and the like.

10 IV. Recombinant Microorganisms

The present invention further features microorganisms, i.e., recombinant microorganisms, that include vectors or genes (e.g., wild-type and/or mutated genes) as described herein. As used herein, the term "recombinant microorganism" includes a microorganism (e.g., bacteria, yeast cell, fungal cell, etc.) that has been genetically altered, modified or engineered (e.g., genetically engineered) such that it exhibits an altered, modified or different genotype and/or phenotype (e.g., when the genetic modification affects coding nucleic acid sequences of the microorganism) as compared to the naturally-occurring microorganism from which it was derived.

In one embodiment, a recombinant microorganism of the present invention is a Gram positive organism (e.g., a microorganism which retains basic dye, for example, crystal violet, due to the presence of a Gram-positive wall surrounding the microorganism). In a preferred embodiment, the recombinant microorganism is a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Corynebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*. In a more preferred embodiment, the recombinant microorganism is of the genus *Bacillus*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus subtilis*, *Bacillus lentimorbus*, *Bacillus lentus*, *Bacillus firmus*, *Bacillus pantothenicus*, *Bacillus amyloliquefaciens*, *Bacillus cereus*, *Bacillus circulans*, *Bacillus coagulans*, *Bacillus licheniformis*, *Bacillus megaterium*, *Bacillus pumilus*, *Bacillus thuringiensis*, *Bacillus halodurans*, and other Group 1 *Bacillus* species, for example, as characterized by 16S rRNA type. In another preferred embodiment, the recombinant microorganism is *Bacillus brevis* or *Bacillus stearothermophilus*. In another preferred embodiment, the recombinant microorganism is selected from the group consisting of *Bacillus licheniformis*, *Bacillus amyloliquefaciens*, *Bacillus subtilis*, and *Bacillus pumilus*.

In another embodiment, the recombinant microorganism is a Gram negative (excludes basic dye) organism. In a preferred embodiment, the recombinant

50367089-032202

microorganism is a microorganism belonging to a genus selected from the group consisting of *Salmonella*, *Escherichia*, *Klebsiella*, *Serratia*, and *Proteus*. In a more preferred embodiment, the recombinant microorganism is of the genus *Escherichia*. In an even more preferred embodiment, the recombinant microorganism is *Escherichia coli*. In another embodiment, the recombinant microorganism is *Saccharomyces* (e.g., *S. cerevisiae*).

A preferred "recombinant" microorganism of the present invention is a microorganism having a deregulated B6 vitamer biosynthesis pathway or enzyme. The term "deregulated" or "deregulation" includes the alteration or modification of at least one gene in a microorganism that encodes an enzyme in a biosynthetic pathway, such that the level or activity of the biosynthetic enzyme in the microorganism is altered or modified. Preferably, at least one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the gene product is enhanced or increased. The phrase "deregulated pathway" can also include a biosynthetic pathway in which more than one gene that encodes an enzyme in a biosynthetic pathway is altered or modified such that the level or activity of more than one biosynthetic enzyme is altered or modified. The ability to "deregulate" a pathway (e.g., to simultaneously deregulate more than one gene in a given biosynthetic pathway) in a microorganism in some cases arises from the particular phenomenon of microorganisms in which more than one enzyme (e.g., two or three biosynthetic enzymes) are encoded by genes occurring adjacent to one another on a contiguous piece of genetic material termed an "operon" (defined herein). Due to the coordinated regulation of genes included in an operon, alteration or modification of the single promoter and/or regulatory element can result in alteration or modification of the expression of more than one gene product encoded by the operon. Alteration or modification of the regulatory element can include, but is not limited to removing the endogenous promoter and/or regulatory element(s), adding strong promoters, inducible promoters or multiple promoters or removing regulatory sequences such that expression of the gene products is modified, modifying the chromosomal location of the operon, altering nucleic acid sequences adjacent to the operon or within the operon such as a ribosome binding site, increasing the copy number of the operon, modifying proteins (e.g., regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of the operon and/or translation of the gene products of the operon, or any other conventional means of deregulating expression of genes routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Deregulation can also involve altering the coding region of one or more genes

60367089-032202

to yield, for example, an enzyme that is feedback resistant or has a higher or lower specific activity.

In another preferred embodiment, a recombinant microorganism is designed or engineered such that at least one B6 vitamer biosynthetic enzyme, is overexpressed. The term "overexpressed" or "overexpression" includes expression of a gene product (*e.g.*, a biosynthetic enzyme) at a level greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. In one embodiment, the microorganism can be genetically designed or engineered to overexpress a level of gene product greater than that expressed in a comparable microorganism which has not been engineered.

Genetic engineering can include, but is not limited to, altering or modifying regulatory sequences or sites associated with expression of a particular gene (*e.g.*, by adding strong promoters, inducible promoters or multiple promoters or by removing regulatory sequences such that expression is constitutive), modifying the chromosomal location of a particular gene, altering nucleic acid sequences adjacent to a particular gene such as a ribosome binding site, increasing the copy number of a particular gene, modifying proteins (*e.g.*, regulatory proteins, suppressors, enhancers, transcriptional activators and the like) involved in transcription of a particular gene and/or translation of a particular gene product, or any other conventional means of deregulating expression of a particular gene routine in the art (including but not limited to use of antisense nucleic acid molecules, for example, to block expression of repressor proteins). Genetic engineering can also include deletion of a gene, for example, to block a pathway or to remove a repressor. In embodiments featuring microorganisms having deleted genes, the skilled artisan will appreciate that at least low levels of certain compounds may be required to be present in or added to the culture medium in order that the viability of the microorganism is not compromised. Often, such low levels are present in complex culture media as routinely formulated. Moreover, in processes featuring culturing microorganisms having deleted genes cultured under conditions such that commercially or industrially attractive quantities of product are produced, it may be necessary to supplement culture media with slightly increased levels of certain compounds.

In another embodiment, the microorganism can be physically or environmentally manipulated to overexpress a level of gene product greater than that expressed prior to manipulation of the microorganism or in a comparable microorganism which has not been manipulated. For example, a microorganism can be treated with or cultured in the presence of an agent known or suspected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription

50367089.032202

and/or translation are enhanced or increased. Alternatively, a microorganism can be cultured at a temperature selected to increase transcription of a particular gene and/or translation of a particular gene product such that transcription and/or translation are enhanced or increased.

5

V. Culturing and Fermenting Recombinant Microorganisms

The term "culturing" includes maintaining and/or growing a living microorganism of the present invention (e.g., maintaining and/or growing a culture or strain). In one embodiment, a microorganism of the invention is cultured in liquid media. In another embodiment, a microorganism of the invention is cultured in solid media or semi-solid media. In a preferred embodiment, a microorganism of the invention is cultured in media (e.g., a sterile, liquid media) comprising nutrients essential or beneficial to the maintenance and/or growth of the microorganism (e.g., carbon sources or carbon substrate, for example carbohydrate, hydrocarbons, oils, fats, fatty acids, organic acids, and alcohols; nitrogen sources, for example, peptone, yeast extracts, meat extracts, malt extracts, soy flour, urea, ammonium sulfate, ammonium chloride, ammonium nitrate and ammonium phosphate; phosphorus sources, for example, phosphoric acid, sodium and potassium salts thereof; trace elements, for example, magnesium, iron, manganese, calcium, copper, zinc, boron, molybdenum, and/or cobalt salts; as well as growth factors such as amino acids, vitamins, and the like).

Preferably, microorganisms of the present invention are cultured under controlled pH. The term "controlled pH" includes any pH which results in production of the desired product. In one embodiment microorganisms are cultured at a pH of about 7. In another embodiment, microorganisms are cultured at a pH of between 6.0 and 8.5. The desired pH may be maintained by any number of methods known to those skilled in the art.

Also preferably, microorganisms of the present invention are cultured under controlled aeration. The term "controlled aeration" includes sufficient aeration (e.g., oxygen) to result in production of the desired product. In one embodiment, aeration is controlled by regulating oxygen levels in the culture, for example, by regulating the amount of oxygen dissolved in culture media. Preferably, aeration of the culture is controlled by agitating the culture. Agitation may be provided by a propeller or similar mechanical agitation equipment, by revolving or shaking the culture vessel (e.g., tube or flask) or by various pumping equipment. Aeration may be further controlled by the passage of sterile air or oxygen through the medium (e.g., through the

60367089-032202

fermentation mixture). Also preferably, microorganisms of the present invention are cultured without excess foaming (*e.g.*, *via* addition of antifoaming agents).

Moreover, microorganisms of the present invention can be cultured under controlled temperatures. The term "controlled temperature" includes any temperature which results in production of the desired product (*e.g.*, a B6 vitamer). In one embodiment, controlled temperatures include temperatures between 15°C and 95°C. In another embodiment, controlled temperatures include temperatures between 15°C and 70°C. Preferred temperatures are between 20°C and 55°C, more preferably between 30°C and 50°C.

Microorganisms can be cultured (*e.g.*, maintained and/or grown) in liquid media and preferably are cultured, either continuously or intermittently, by conventional culturing methods such as standing culture, test tube culture, shaking culture (*e.g.*, rotary shaking culture, shake flask culture, etc.), aeration spinner culture, or fermentation. In a preferred embodiment, the microorganisms are cultured in shake flasks. In a more preferred embodiment, the microorganisms are cultured in a fermentor (*e.g.*, a fermentation process). Fermentation processes of the present invention include, but are not limited to, batch, fed-batch and continuous processes or methods of fermentation. The phrase "batch process" or "batch fermentation" refers to a closed system in which the composition of media, nutrients, supplemental additives and the like is set at the beginning of the fermentation and not subject to alteration during the fermentation, however, attempts may be made to control such factors as pH and oxygen concentration to prevent excess media acidification and/or microorganism death. The phrase "fed-batch process" or "fed-batch" fermentation refers to a batch fermentation with the exception that one or more substrates or supplements are added (*e.g.*, added in increments or continuously) as the fermentation progresses. The phrase "continuous process" or "continuous fermentation" refers to a system in which a defined fermentation media is added continuously to a fermentor and an equal amount of used or "conditioned" media is simultaneously removed, preferably for recovery of the desired product (*e.g.*, a B6 vitamer). A variety of such processes have been developed and are well-known in the art.

The phrase "culturing under conditions such that a desired compound is produced" includes maintaining and/or growing microorganisms under conditions (*e.g.*, temperature, pressure, pH, duration, etc.) appropriate or sufficient to obtain production of the desired compound or to obtain desired yields of the particular compound being produced. For example, culturing is continued for a time sufficient to produce the desired amount of a compound (*e.g.*, a B6 vitamer). Preferably, culturing is continued for a time sufficient to substantially reach suitable production of the compound (*e.g.*, a

60367089-032202

150367089-032202

- time sufficient to reach a suitable concentration of a B6 vitamer). In one embodiment, culturing is continued for about 12 to 24 hours. In another embodiment, culturing is continued for about 24 to 36 hours, 36 to 48 hours, 48 to 72 hours, 72 to 96 hours, 96 to 120 hours, 120 to 144 hours, or greater than 144 hours. The methodology of the present
- 5 invention can further include a step of recovering a desired compound (*e.g.*, a B6 vitamer). The term "recovering" a desired compound includes extracting, harvesting, isolating or purifying the compound from culture media. Recovering the compound can be performed according to any conventional isolation or purification methodology known in the art including, but not limited to, treatment with a conventional resin (*e.g.*,
- 10 anion or cation exchange resin, non-ionic adsorption resin, etc.), treatment with a conventional adsorbent (*e.g.*, activated charcoal, silicic acid, silica gel, cellulose, alumina, etc.), alteration of pH, solvent extraction (*e.g.*, with a conventional solvent such as an alcohol, ethyl acetate, hexane and the like), dialysis, filtration, concentration, crystallization, recrystallization, pH adjustment, lyophilization and the like. For
- 15 example, a compound can be recovered from culture media by first removing the microorganisms from the culture. The resulting solutions are then passed through or over a cation exchange resin to remove cations and/or through or over an anion exchange resin to purify or concentrate the desired product. The resulting compound can subsequently be converted to a salt (*e.g.*, a chloride or sulfate salt) by ion exchange.
- 20 Preferably, a desired compound of the present invention is "extracted," "isolated" or "purified" such that the resulting preparation is substantially free of other media components (*e.g.*, free of media components and/or fermentation byproducts). The language "substantially free of other media components" includes preparations of the desired compound in which the compound is separated from media components or
- 25 fermentation byproducts of the culture from which it is produced. In one embodiment, the preparation has greater than about 80% (by dry weight) of the desired compound (*e.g.*, less than about 20% of other media components or fermentation byproducts), more preferably greater than about 90% of the desired compound (*e.g.*, less than about 10% of other media components or fermentation byproducts), still more preferably greater than
- 30 about 95% of the desired compound (*e.g.*, less than about 5% of other media components or fermentation byproducts), and most preferably greater than about 98-99% desired compound (*e.g.*, less than about 1-2% other media components or fermentation byproducts). When the desired compound has been derivatized to a salt, the compound is preferably further free of chemical contaminants associated with the
- 35 formation of the salt. When the desired compound has been derivatized to an alcohol, the compound is preferably further free of chemical contaminants associated with the formation of the alcohol.

In an alternative embodiment, the desired compound is not purified from the microorganism, for example, when the microorganism is biologically non-hazardous (*e.g.*, safe). For example, the entire culture (or culture supernatant) can be used as a source of product (*e.g.*, crude product). In one embodiment, the culture (or culture supernatant) is used without modification. In another embodiment, the culture (or culture supernatant) is concentrated. In yet another embodiment, the culture (or culture supernatant) is dried or lyophilized.

Preferably, a production method of the present invention results in production of the desired compound, *e.g.*, a B6 vitamer, at a significantly high yield. The phrase "significantly high yield" includes a level of production or yield which is sufficiently elevated or above what is usual for comparable production methods, for example, which is elevated to a level sufficient for commercial production of the desired product (*e.g.*, production of the product at a commercially feasible cost). In one embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 5 mg/L. In another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 10 mg/L. In another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 50 mg/L. In yet another embodiment, the invention features a production method that includes culturing a recombinant microorganism under conditions such that the desired product (*e.g.*, a B6 vitamer) is produced at a level greater than 150 mg/L.

Depending on the biosynthetic enzyme or combination of biosynthetic enzymes manipulated, it may be desirable or necessary to provide (*e.g.*, feed) microorganisms of the present invention at least one biosynthetic precursor such that the desired compound or compounds are produced. The term "biosynthetic precursor" or "precursor" includes an agent or compound which, when provided to, brought into contact with, or included in the culture medium of a microorganism, serves to enhance or increase biosynthesis of the desired product. In one embodiment, the biosynthetic precursor or precursor is glutamine. In another embodiment, the biosynthetic precursor or precursor is ribose. The amount of glutamine or ribose added is preferably an amount that results in a concentration in the culture medium sufficient to enhance productivity of the microorganism (*e.g.*, a concentration sufficient to enhance production of a B6 vitamer). The term "excess ribose or glutamine" includes ribose or glutamine levels increased or higher than those routinely utilized for culturing the microorganism in

question. For example, culturing the *Bacillus* microorganisms described in the instant Examples is routinely done in the presence of about 0-5 g/L ribose or glutamine. Accordingly, excess ribose or glutamine levels can include levels of about 5-10 g/L or more preferably about 5-20 g/L ribose or glutamine. Biosynthetic precursors of the
5 present invention can be added in the form of a concentrated solution or suspension (e.g., in a suitable solvent such as water or buffer) or in the form of a solid (e.g., in the form of a powder). Moreover, biosynthetic precursors of the present invention can be added as a single aliquot, continuously or intermittently over a given period of time.

10

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein
15 by reference.

60367089-032202

EXAMPLES

EXAMPLE 1: Biological assay for B6 vitamers using *Saccharomyces uvarum*.

Quantitation of B6 vitamers in supernatants of cultures of micro-organisms or extracts of organisms that have been genetically modified to increase production of B6 vitamers is conveniently done using *Saccharomyces uvarum* (formerly and still often named *S. carlsbergensis*) strain ATCC 9080 as the indicator strain or test organism. The method is essentially that described in the Difco Manual (1984, Difco Laboratories, Detroit, MI, 10th Edition, pp. 1104-1106), with the modification that 50 mg/liter of streptomycin sulfate is added to the liquid growth medium for the test organism. However, any other appropriate indicator organism may be used, together with a medium that is appropriate for that organism that is free of B6 vitamers. For example, an *E. coli* *pxdB* mutant can be used in a standard minimal medium that is well known in the art, such as M9 glucose minimal medium (Miller, J., (1972) Experiments in Molecular Genetics, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).

When using *S. uvarum* strain ATCC 9080 as the indicator strain, Bacto Pyridoxine Y Medium (Difco Laboratories, available through VWR Scientific, Inc.), supplemented with 50 mg/liter streptomycin sulfate, is used for the serial dilutions, and PN, PL, or PM is used to generate the standard curve. The responses to these three standard compounds are almost identical to each other with *S. uvarum* strain ATCC 9080 (Figure 3).

EXAMPLE 2: Deletion of a portion of the *yaaDE* operon in *B. subtilis*.

The *SOR* and *SNO* genes of *Cercospora nicotianae* were originally identified by mutations that lead to hypersensitivity to singlet oxygen-generating reagents (Ehrenschaft, M., et al. (1999) *Proc. Natl. Acad. Sci. USA* 96: 9347-9378). Mutations in either of these genes also lead to PL auxotrophy. The protein sequences obtained from translation of the *SOR* and *SNO* open reading frames were used as homology probes to search through the *B. subtilis* genome sequence using the BLAST homology search program of the Subtilist website. The *SOR* protein was significantly homologous to the YaaD protein, and the *SNO* protein was significantly homologous to the YaaE protein. Moreover, the genes encoding the YaaD and YaaE proteins (namely *yaaD* and *yaaE*) occur adjacent to each other on the *B. subtilis* chromosome as a two gene operon.

General methods for growth, storage, transformation, and molecular biology of *B. subtilis* strains are given in Harwood, C., and Cutting, S. (1990), *Molecular Biological Methods for Bacillus*, John Wiley and Sons, New York, NY, hereby

20220906 090703

incorporated in its entirety by reference. The *yaaDE* operon DNA sequence was amplified using the Polymerase Chain Reaction (PCR) with Pfu Turbo DNA polymerase (Stratagene, Inc., used according to the manufacturer's instructions). The DNA primers used were RY395 (SEQ ID NO:1) and RY396 (SEQ ID NO:2). RY395, the upstream
5 primer, introduces an *XbaI* site and artificial ribosome binding site. RY396, the downstream primer, introduces a *BamHI* site. The template DNA was chromosomal DNA isolated from wild type *B. subtilis* strain PY79. The blunt ended PCR product was ligated into the *EcoRV* site of pGEM5Zf(+) (Promega, Inc.) to give plasmid pAN368. Next, a gram positive chloramphenicol resistance gene on a blunt DNA fragment was
10 ligated into pAN368 that had been cut with *HpaI*, to give plasmid pDX1F (SEQ ID NO:5, Figure 4). pDX1F therefore is deleted for a portion of *yaaD* and a portion of *yaaE*. pDX1F was used to transform wild type *B. subtilis* strain PY79 to 5 mg/liter chloramphenicol resistance, and a double crossover event was confirmed using PCR and the same primers used to clone *yaaDE*. The resulting strain was named PX1.

15 PX1 was able to grow on Spizizen's minimal medium with trace elements (SMM) (Harwood, C., and Cutting, S. (1990) Molecular Biological Methods for *Bacillus*, John Wiley and Sons, New York, NY, pp. 548-549) supplemented with 2 μ M pyridoxal HCl (Sigma-Aldrich Chemical Co.), but it did not grow without the supplement. Thus it was established that at least one of *yaaD* or *yaaE* is required for
20 PLP synthesis in *B. subtilis*.

EXAMPLE 3: Deletion of *yhaF* in *B. subtilis*.

The protein sequence of the *E. coli pdcF* gene was used as a probe to search the *B. subtilis* genome as described in Example 1. The only significant homolog
25 was *yhaF*. In a fashion similar to that of Example 1, the *yhaF* was cloned and deleted from the chromosome of PY79 using plasmid pDX11F (SEQ ID NO:6, Figure 5), to give strain PX11. The PCR primers used to clone *yhaF* were RY407 (SEQ ID NO:3) and RY408 (SEQ ID NO:4). The restriction sites used for insertion of the antibiotic resistance gene were the *PshAI* and *EheI* sites in the *yhaF* coding region. PX11 is a
30 serine auxotroph, but not a PL auxotroph. By comparison to *E. coli*, it appears that *yhaF* functions in serine synthesis and probably encodes the equivalent of *SerC*, but that the YhaF protein is not required for PLP synthesis in *B. subtilis*. Therefore, it is established that sequence homology does not necessarily imply functional homology.

EXAMPLE 4: Overexpression of the *yaaDE* operon in *B. subtilis*.

The *XbaI* to *BamHI* fragment from pAN368 that contains the *yaaDE* operon and artificial ribosome binding site was inserted into either of two expression

60367089-032202

vectors, to yield plasmids pDX14R (SEQ ID NO:7) and pDX17R (SEQ ID NO:8), respectively. In pDX14R and pDX17R, the *yaaDE* operon is expressed from the strong constitutive *B. subtilis* phage SP01 promoters, P_{26} and P_{15} , respectively (see Figures 6 and 7).

- 5 pDX14R and pDX17R were each transformed into wild type *B. subtilis* strain PY79, selecting for chloramphenicol resistance. The plasmids integrate into the chromosome at the *yaaDE* locus by single crossover. The resulting strains were named PX14 and PX17, respectively.

- 10 PX14 and PX17 were grown for 48 hours at 37°C in 5 ml test tube cultures in a roller drum at about 100 rotations per minute. The culture medium was SVY (20 g Difco Veal Infusion Broth, 5 g Difco Yeast Extract, 2 g ammonium sulfate, 5 g sodium glutamate, and 30 g glucose per liter, buffered with 200 mM potassium phosphate, pH 7.0). Cells were removed by centrifugation followed by sterile filtration (Millipore 0.45 micron), and the supernatant solutions were assayed for PL equivalents
- 15 using the biological assay described in Example 1. The parent strain, PY79 was grown and processed in similar fashion as a control. The uncultured SVY medium was assayed as another control, since it was likely that the SVY medium contained a measurable level of B6 vitamers. The results are shown in Table 2, below.

20 **Table 2: Production of B6 vitamers by *Bacillus subtilis* derivatives in 48 hour test tube cultures grown in SVY**

Strain	Cassette	Integration Target	OD ₆₀₀	Total B6 Vitamers ¹ mg/liter	Net B6 Vitamers ² mg/liter
PX14	$P_{26}yaaDE$	<i>yaaDE</i>	17	7.2	7.0
PX17	$P_{15}yaaDE$	<i>yaaDE</i>	17	4.9	4.7
PX1	$\Delta yaaDE$	<i>yaaDE</i>	8	0.4	0.2
PY79	-	-	19	0.8	0.6
(Medium)	-	-	0.08	0.2	(0)

¹ Sum of PN, PL, PM, and derivatives thereof that can be utilized by pyridoxine indicator strain *S. carlbergensis* as a source of vitamin B6 for growth.

- 25 ² Calculated by subtracting the amount assayed in the medium.

- 30 After subtracting the B6 vitamers contained in the medium, strain PX14 produced 7.0 mg/liter PL equivalents, while the parent PY79 produced only 0.6 mg/liter of PL equivalents. Thus, expression of the *yaaDE* operon has been shown to be rate limiting for B6 vitamer production in *B. subtilis*. Moreover, a genetically modified

150367089-032202

strain, where this rate limiting step was enhanced, produced more than a ten-fold increase in B6 vitamers secretion compared to that of the parent.

EXAMPLE 5: Complementation of *E. coli* *pdx* mutants by plasmids that express the *B. subtilis* *yaaDE* operon.

5 Plasmid pDX14R, described above in Example 4, was used to transform various *E. coli* strains that contained mutations that lacked function in each of the known genes involved in PLP biosynthesis (except for *dxs*, which is an essential gene for *E. coli*). The selection was for resistance to 250 mg/liter ampicillin. Each transformant
10 was then tested for growth on minimal medium (SMM with 0.5 % glucose, see Example 2) supplemented with 100 mg/liter serine, and compared to growth of its respective untransformed parent on the same medium. All mutations tested were complemented by pDX14R. Specifically, *pdxA*, *pdxB*, *pdxF*, *pdxJ*, and *pdxH*, were all complemented by pDX14R. Therefore, expression of the *B. subtilis* *yaaDE* operon in *E. coli* is sufficient
15 for PLP biosynthesis, even in the absence of any one of the above functional *pdx* genes. Several important and unexpected conclusions or inferences can be drawn from these results. First, the substrate(s) for the enzyme(s) encoded by *yaaDE* must be present in *E. coli*, even when a biosynthetic intermediate normally used to make PLP is absent or greatly reduced. Second, PNP or PLP is possibly the product of the enzyme(s) encoded
20 by *yaaDE*. Third, since an early block in the *E. coli* PLP biosynthetic pathway (for example that in a *pdxB* mutant) does not prevent *yaaDE* from complementation, the substrates for the enzyme(s) encoded by *yaaDE* are not likely to be the same as for the last step in PNP or PLP synthesis in wild type *E. coli*. These unexpected results lead to the possibility of producing B6 vitamers using *B. subtilis* *yaaDE* or the homologous
25 genes from another organism (for example, but not limited to, *SOR* and *SNO* from *Cercospora nicotianae* or *PDX1* and *PDX2* from *S. cerevisiae*) in a heterologous host species, including, but not limited to, *E. coli* and *Oryza sativa*.

EXAMPLE 6: Overexpression of the *yaaDE* operon in *E. coli*.

30 Plasmids pDX14R and pDX17R were transformed into *E. coli* strain DH5 α (New England Biolabs), selecting for ampicillin resistance. The transformants were grown for 48 hours in 5 ml test tube cultures at 37°C, and the supernatants were worked up as in Example 3. The assay results for PL equivalents are shown in Table 3, below.

Table 3: Production of B6 vitamers by *Escherichia coli* harboring plasmids containing engineered *Bacillus subtilis* genes¹

Strain	Plasmid Cassette	OD ₆₀₀	Total B6 Vitamers ² mg/liter	Net B6 Vitamers ³ mg/liter
DH5α	<i>P₂₆yaaDE</i>	7.6	3.2	3.1
DH5α	<i>P₁₅yaaDE</i>	8.2	3.2	3.1
DH5α	-	9	0.1	(0)

¹*E. coli* test tube cultures are grown in SVY for 48 hours.

²Sum of PN, PL, PM, and derivatives thereof that can be utilized by pyridoxine indicator strain *S. carlbergensis* as a source of vitamin B6 for growth.

³ Calculated by subtracting the amount assayed in DH5α not containing plasmid.

Thus it has been shown that the *yaaD* and *yaaE* genes can be expressed in a heterologous host strain, and B6 vitamers can still be overproduced. By extension of this approach, the *yaaD* and *yaaE* genes of *B. subtilis* can be overexpressed in any organism where an overexpression system exists, and in the resulting strains, B6 vitamers will be overproduced. Overproduction of the rate limiting enzyme for B6 vitamer production in any organism that is capable of producing B6 vitamers will lead to overproduction of B6 vitamers.

The YaaD and YaaE protein sequences were used as probes to search the NCBI database for homologs in plants using the BLAST™ program which can be found at the National Center for Biotechnology Information website (Altschul S.F (1990) *J. Mol. Biol.* 215(3):403-10). Several homologs of YaaD were found in several genera of plants, including *Arabidopsis*, *Oryza*, *Ginkgo*, *Hevea*, *Phaseolus*, and *Stellaria*. Two homologs of YaaE were found in *Arabidopsis thaliana*. However, no homologs of *pdxA* and *pdxJ* were found. Therefore the plant kingdom appears to use the Type B Pathway for B6 vitamer biosynthesis. Thus for example, overexpression of the YaaD homolog (GenBank accession number AAL73561) from *Oryza sativa* (rice), and the *A. thaliana* homolog of YaaE (GenBank accession number AB011483) together in a plant using methods well know in the art, such as expression from the Cauliflower Mosaic Virus 35S promoter, will lead to overproduction of B6 vitamers in that plant.

EXAMPLE 7: Other routes to increasing the activity of enzymes involved in B6 vitamer synthesis.

The overexpression of the *yaaDE* operon leads to an increase in the amount of the encoded enzyme(s), which in turn leads to an increase in the total activity of said enzyme(s). Increase in this activity leads to an increase in the production B6 vitamer. Other methods can be used to increase the activity of the relevant enzyme(s)

60367089-032202

under conditions of B6 vitamer production. For example, in addition to increasing the amount of a relevant enzyme(s), the total activity of the relevant enzyme(s) can be increased by mutating the gene(s) to increase the specific activity of the enzyme(s), and/or by mutating the gene(s) to encode a feedback resistant variant of the enzyme(s).

- 5 Such desirable mutations can be obtained by screening large numbers of mutants for the increased activity as evidenced by an increase in B6 vitamer production as described in Example 4, or by selecting for mutants that are resistant to inhibitors that are specific for the PLP biosynthetic pathway, and screening among those mutants for an increase in B6 vitamer production. Examples of such inhibitors are isoniazid, iproniazid, and
- 10 ginkgotoxin (4'-methoxy pyridoxine) (Dempsey and Arcement (1971) J. Bacteriol. 107(2): 580-582; Pflug, W., and Lingens, F., (1978) Hoppe-Seyler's Z. Physiol. Chem. 359: 559-570; Fiehe, K., et al., (2000) J. Nat. Prod. 63(2): 185-189).

15 **EXAMPLE 8: Processing of biosynthetic B6 vitamers.**

- A B6 vitamer produced by a genetically modified organism of the invention can be harvested and processed into a format that is appropriate for commercial use. For example, after culturing a B6 vitamer producing micro-organism in liquid culture, the entire culture, including cells can be dried by evaporation or by spray
- 20 drying, and the resulting powder can be mixed into animal feeds. Alternatively, the cells can be first removed by centrifugation or filtration, and the resulting supernatant solution can be dried as described above. As another alternative, the B6 vitamer can be purified from the culture broth by techniques well known in the art, such as filtration, reverse osmosis, column chromatography (ion exchange, hydrophobic or hydrophilic
- 25 adsorption, gel filtration, etc.), solvent extraction, precipitation, distillation, evaporation, and the like. If the B6 vitamer producing organism is a plant, then the appropriate portion of the plant (for example the leaves, stems, roots, flowers, fruits, seeds, or any combination thereof) can be harvested and processed. For example the plant material can be dried and used directly, or the material can be pulverized or ground and the B6
- 30 vitamer extracted and/or processed as described above for cultures.

The production organism can be a micro-organism that normally inhabits the gut of humans or an animal if interest (for example one of many bacteria of the genus *Lactobacillus*, such as *L. acidophilus*), and the B6 vitamer can be delivered by ingestion of the organism.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the

5 following claims.

20220715 16:30:49

UNITED STATES PATENT AND TRADEMARK OFFICE
DOCUMENT CLASSIFICATION BARCODE SHEET



Claims

5

Level - 2
Version 1.1
Updated - 8/01/01

20220809.032202

What is claimed:

1. An organism that has been genetically modified to comprise a recombinant DNA molecule that results in the increase of the activity of one or more enzymes that catalyze(s) a step in the biosynthesis of a B6 vitamer, such that B6 vitamer production from said modified organism is increased compared to B6 production in an unmodified parent organism.
2. The organism of claim 1, wherein B6 vitamer production is at least ten-fold higher than from the unmodified parent organism.
3. The organism of claim 1, wherein said enzyme is one or more of YaaD or YaaE.
4. The organism of claim 1, wherein said organism is genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer.
5. The organism of claim 4, wherein at least one of said genes is a *yaaD* gene.
6. The organism of claim 4, wherein at least one of said genes is a *yaaE* gene.
7. The organism of claim 4, wherein at least two of said genes are *yaaD* and *yaaE* genes.
8. The organism of claim 4, wherein said organism is a *Bacillus* strain.
9. The organism of claim 4, wherein said organism is *Bacillus subtilis*.
10. The organism of claim 4, wherein said organism is *Escherichia coli*.

60367089-032202

11. The organism of claim 10, wherein said genes are selected from the group consisting of *E. coli epd*, *pdxA*, *pdxJ*, *pdxF*, *pdxB*, *pdxH* or *dxs*.

12. The organism of any one of claims 1-11, wherein said organism is grown in a liquid culture and the total B6 vitamer concentration in the culture supernatant is at least 7.0 mg/liter.

13. A method of producing a B6 vitamer comprising culturing a microorganism that has been genetically modified to overexpress one or more genes that encodes an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer, such that B6 vitamer production from said modified organism is increased compared to B6 production in an unmodified parent organism, under conditions such that the B6 vitamer is produced.

14. The method of claim 13, wherein said enzyme is one or more of YaaD or YaaE.

15. The method of claim 13, wherein at least one of said genes is a *yaaD* gene.

16. The method of claim 13, wherein at least one of said genes is a *yaaE* gene.

17. The method of claim 13, wherein said genes are contained on the *yaaDE* operon.

18. The method of claim 13, wherein the B6 vitamer is pyridoxine.

19. The method of claim 13, wherein the B6 vitamer is pyridoxal.

20. The method of claim 13, wherein the B6 vitamer is pyridoxamine.

21. The method of claim 13, wherein the said genes are bacterial-derived.

22. The method of claim 13, wherein said genes are derived from *Bacillus*.

150367089-032202

23. The method of claim 13, wherein said genes are derived from *Bacillus subtilis*.
- 5 24. The method of claim 13, wherein the microorganism is Gram positive.
25. The method of claim 13, wherein the microorganism is a microorganism belonging to a genus selected from the group consisting of *Bacillus*,
10 *Corynebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*.
26. The method of claim 13, wherein the microorganism is of the genus *Bacillus*.
- 15 27. The method of claim 13, wherein the microorganism is *Bacillus subtilis*.
28. The method of claim 13, further comprising recovering the B6 vitamer.
20
29. A method of producing a B6 vitamer comprising culturing a microorganism that overexpresses at least one *Bacillus* B6 vitamer biosynthetic gene under conditions such that the B6 vitamer is produced.
- 25 30. The method of claim 29, wherein the microorganism overexpresses at least one *Bacillus subtilis* B6 vitamer biosynthetic enzyme.
31. The method of claim 29, wherein the B6 vitamer is pyridoxine.
- 30 32. The method of claim 29, wherein the B6 vitamer is pyridoxal.
33. The method of claim 29, wherein the B6 vitamer is pyridoxamine.
34. The method of claim 29, wherein the microorganism
35 overexpresses at least two B6 vitamer biosynthetic enzymes.

60367089-032202

35. The method of claim 29, wherein the microorganism is Gram positive.
36. The method of claim 29, wherein the microorganism is Gram negative.
37. The method of claim 29, wherein the microorganism is a microorganism belonging to a genus selected from the group consisting of *Bacillus*, *Corynebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*.
38. The method of claim 29, wherein the microorganism is of the genus *Bacillus*.
39. The method of claim 29, wherein the microorganism is *Bacillus subtilis*.
40. The method of claim 29, further comprising recovering the B6 vitamer.
41. A recombinant microorganism that overexpresses at least one *Bacillus* B6 vitamer biosynthetic gene.
42. A recombinant microorganism that overexpresses at least one *Bacillus* B6 vitamer biosynthetic enzyme.
43. The method of claim 42, wherein said enzyme is YaaD or YaaE.
44. The recombinant microorganism of claim 41 that overexpresses at least one *Bacillus subtilis* B6 vitamer biosynthetic gene.
45. The recombinant microorganism of claim 41, wherein the B6 vitamer biosynthetic gene is selected from the group consisting of *yaaD* and *yaaE*.
46. The recombinant microorganism of claim 41, that is Gram positive.

47. The recombinant microorganism of claim 41 belonging to a genus selected from the group consisting of *Bacillus*, *Corynebacterium*, *Lactobacillus*, *Lactococci* and *Streptomyces*.
- 5 48. The recombinant microorganism of claim 41 belonging to the genus *Bacillus*.
49. The recombinant microorganism of claim 41 which is *Bacillus subtilis*.
- 10 50. A recombinant microorganism selected from the group consisting of PX14 and PX17.
51. A vector comprising a nucleic acid sequence that encodes at least one *Bacillus* B6 vitamer biosynthetic gene operably linked to regulatory sequences.
- 15 52. The vector of claim 51, comprising a nucleic acid sequence that encodes at least one *Bacillus subtilis* B6 vitamer biosynthetic gene.
- 20 53. The vector of claim 51, wherein the regulatory sequences comprise a constitutively active promoter.
54. The vector of claim 51, wherein the constitutively active promoter comprises P_{15} (SEQ ID NO:9) or P_{26} (SEQ ID NO:10) sequences.
- 25 55. The vector of claim 51, wherein the regulatory sequences comprise at least one artificial ribosome binding site (RBS).
56. A vector selected from the group consisting of pDX14R and pDX17R.
- 30 57. A recombinant microorganism comprising the vector of claim 56.
58. An isolated nucleic acid molecule that encodes at least one *Bacillus* B6 vitamer biosynthetic gene.
- 35

60367089.032202

59. The isolated nucleic acid molecule of claim 58 that encodes at least one *Bacillus subtilis* B6 vitamer biosynthetic gene.

60. An isolated *Bacillus* B6 vitamer biosynthetic enzyme polypeptide.

5

61. An isolated *Bacillus subtilis* B6 vitamer biosynthetic enzyme polypeptide.

60367089.032202

**METHODS AND ORGANISMS FOR
PRODUCTION OF B6 VITAMERS**

5 Abstract of the Disclosure

The present invention features methods of producing B6 vitamers that involve culturing an organism overexpressing an enzyme that catalyzes a step in the biosynthesis of a B6 vitamer under conditions such that a B6 vitamer is produced. The

- 10 present invention further features methods of producing B6 vitamers that involve culturing recombinant microorganisms that overexpress at least one B6 vitamer biosynthetic gene, *e.g.*, *yaaD* or *yaaE*.

60367089.032202

Figure 1




Figure 2




Figure 3






Figure 4. Structure of pDX1F



2022E0-68079E09

Figure 5. Structure of pDX11F



20220708079003

1960
 1961
 1962
 1963
 1964
 1965
 1966
 1967
 1968
 1969
 1970
 1971
 1972
 1973
 1974
 1975
 1976
 1977
 1978
 1979
 1980
 1981
 1982
 1983
 1984
 1985
 1986
 1987
 1988
 1989
 1990
 1991
 1992
 1993
 1994
 1995
 1996
 1997
 1998
 1999
 2000
 2001
 2002
 2003
 2004
 2005
 2006
 2007
 2008
 2009
 2010
 2011
 2012
 2013
 2014
 2015
 2016
 2017
 2018
 2019
 2020
 2021
 2022
 2023
 2024
 2025
 2026
 2027
 2028
 2029
 2030
 2031
 2032
 2033
 2034
 2035
 2036
 2037
 2038
 2039
 2040
 2041
 2042
 2043
 2044
 2045
 2046
 2047
 2048
 2049
 2050
 2051
 2052
 2053
 2054
 2055
 2056
 2057
 2058
 2059
 2060
 2061
 2062
 2063
 2064
 2065
 2066
 2067
 2068
 2069
 2070
 2071
 2072
 2073
 2074
 2075
 2076
 2077
 2078
 2079
 2080
 2081
 2082
 2083
 2084
 2085
 2086
 2087
 2088
 2089
 2090
 2091
 2092
 2093
 2094
 2095
 2096
 2097
 2098
 2099
 2100
 2101
 2102
 2103
 2104
 2105
 2106
 2107
 2108
 2109
 2110
 2111
 2112
 2113
 2114
 2115
 2116
 2117
 2118
 2119
 2120
 2121
 2122
 2123
 2124
 2125
 2126
 2127
 2128
 2129
 2130
 2131
 2132
 2133
 2134
 2135
 2136
 2137
 2138
 2139
 2140
 2141
 2142
 2143
 2144
 2145
 2146
 2147
 2148
 2149
 2150
 2151
 2152
 2153
 2154
 2155
 2156
 2157
 2158
 2159
 2160
 2161
 2162
 2163
 2164
 2165
 2166
 2167
 2168
 2169
 2170
 2171
 2172
 2173
 2174
 2175
 2176
 2177
 2178
 2179
 2180
 2181
 2182
 2183
 2184
 2185
 2186
 2187
 2188
 2189
 2190
 2191
 2192
 2193
 2194
 2195
 2196
 2197
 2198
 2199
 2200
 2201
 2202
 2203
 2204
 2205
 2206
 2207
 2208
 2209
 2210
 2211
 2212
 2213
 2214
 2215
 2216
 2217
 2218
 2219
 2220
 2221
 2222
 2223
 2224
 2225
 2226
 2227
 2228
 2229
 2230
 2231
 2232
 2233
 2234
 2235
 2236
 2237
 2238
 2239
 2240
 2241
 2242
 2243
 2244
 2245
 2246
 2247
 2248
 2249
 2250
 2251
 2252
 2253
 2254
 2255
 2256
 2257
 2258
 2259
 2260
 2261
 2262
 2263
 2264
 2265
 2266
 2267
 2268
 2269
 2270
 2271
 2272
 2273
 2274
 2275
 2276
 2277
 2278
 2279
 2280
 2281
 2282
 2283
 2284
 2285
 2286
 2287
 2288
 2289
 2290
 2291
 2292
 2293
 2294
 2295
 2296
 2297
 2298
 2299
 2300
 2301
 2302
 2303
 2304
 2305
 2306
 2307
 2308
 2309
 2310
 2311
 2312
 2313
 2314
 2315
 2316
 2317
 2318
 2319
 2320
 2321
 2322
 2323
 2324
 2325
 2326
 2327
 2328
 2329
 2330
 2331
 2332
 2333
 2334
 2335
 2336
 2337
 2338
 2339
 2340
 2341
 2342
 2343
 2344
 2345
 2346
 2347
 2348
 2349
 2350
 2351
 2352
 2353
 2354
 2355
 2356
 2357
 2358
 2359
 2360
 2361
 2362
 2363
 2364
 2365
 2366
 2367
 2368
 2369
 2370
 2371
 2372
 2373
 2374
 2375
 2376
 2377
 2378
 2379
 2380
 2381
 2382
 2383
 2384
 2385
 2386
 2387
 2388
 2389
 2390
 2391
 2392
 2393
 2394
 2395
 2396
 2397
 2398
 2399
 2400
 2401
 2402
 2403
 2404
 2405
 2406
 2407
 2408
 2409
 2410
 2411
 2412
 2413
 2414





FIGURE 7. Structure of pDX17R



SEQUENCE LISTING

<110> Yocum, R. Rogers
Williams, Mark K.
Pero, Janice G.

<120> METHODS AND ORGANISMS FOR PRODUCTION OF B6 VITAMERS

<130> BGI-152-1

<160> 19

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 1

ccctctagag gaggagaaaa catggctcaa acagggtactg aacgtg 46

<210> 2

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 2

cccggatcct caactgtttt atacaagtgc cttttgctta tattc 45

<210> 3

<211> 49

<212> DNA

<213> Artificial Sequence.

<220>

<223> primer

<400> 3

ccctctagag gaggagacat aatggaacgt acaacgaatt ttaacgcag 49

<210> 4

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> primer

<400> 4

cccggatccc ggacggtttg catagccaga ctttttactc a 41

<210> 5

<211> 5322

<212> DNA

50367089-032202

<213> Artificial Sequence

<220>

<223> plasmid - pDX1F

<400> 5

tgccgcgcta cagggcgcgt ccattcgcca ttcaggctgc gcaactgttg ggaagggcga 60
tcggtgcggg cctcttcgct attacgccag ctggcgaaag ggggatgtgc tgcaaggcga 120
ttaagttggg taacgccagg gttttcccag tcacgacgtt gtaaaacgac ggccagtga 180
ttgtaatacg actcactata gggcgcaattg ggcccgacgt cgcagtctcc cggccgccat 240
ggccgcggga tccctctaga ggaggagaaa acatggctca aacagggtact gaacgtgtaa 300
aacgcggaat ggcagaaatg caaaaaggcg gcgtcatcat ggacgtcatc aatgcggaac 360
aagcgaataat cgtggaagaa gctggagctg tcgctgtaat ggcgctagaa cgtgtgccag 420
cagatattcg cgcggctgga ggagttgccc gtatggctga ccctacaatc gtggaagaag 480
taatgaatgc agtatctatc ccggtaattg caaaagcgcg tatcgacatc attgttgaag 540
cgctgtgctg tgaagctatg ggtgttgact atattgatga aagtgaagtt ctgacgccgg 600
ctgacgaaga atttcattta aataaaaatg aatacacagt tcctttgtgc tgtggctgcc 660
gtgatcttgg tgaagcaaca cgccgtattg cgggaaggctg ttctatgctt cgcacaaaag 720
gtgagcctgg aacaggtaat attgttgagg ctgttcgcca tatgcgtaaa gttatcacta 780
gtgcggccgc ctgcaggctg accatatggg agaggcgccc gcgtcgacca atagttaccc 840
ttattatcaa gataagaaag aaaaggattt ttcgctacgc tcaaatcctt taaaaaaca 900
caaaagacca catTTTTTaa tgtggctctt attcttcaac taaagcacc attagttcaa 960
caaacgaaaa ttggataaag tgggatattt ttaaaatata tatttatgtt acagtaatat 1020
tgacttttaa aaaaggattg attctaatag agaaagcaga caagtaagcc tcctaaattc 1080
acttttagata aaaatttagg aggcataatc aatgaacttt aataaaattg atttagacaa 1140
ttggaagaga aaagagatat ttaatcatta tttgaaccaa caaacgaact ttagtataac 1200
cacagaaatt gatattagtg ttttataacc aaacataaaa caagaaggat ataaatttta 1260
ccctgcattt attttcttag tgacaagggt gataaactca aatacagctt ttagaactgg 1320
ttacaatagc gacggagagt taggttattg ggataagtta gagccacttt atacaatttt 1380
tgatgggtga tctaaaacat tctctggatg ttggactcct gtaaagaatg acttcaaaga 1440
gttttatgat ttataccttt ctgatgtaga gaaatataat gggtcgggga aattgtttcc 1500
caaaacacct atacctgaaa atgctttttc tctttctatt attccatgga cttcatttac 1560
tgggtttaac ttaaataatc ataataatag taattacctt ctaccatta ttacagcagg 1620
aaaattcatt aataaaggta attcaatata tttaccgcta tctttacagg tacatcattc 1680
tgtttgtgat ggttatcatg caggattggt tatgaactct attcaggaat tgtcagatag 1740
gcctaatgac tggcttttat aatatgagtt accgagctg gtacttttta cagtccggtt 1800
tctaattgtc ctacactgcc ccgttagttg aagaaggttt ttatattaca gctccggtag 1860
cgggctccca acgcgttgga tgcatagctt gagtattcta tagtgtcacc taaatagctt 1920
ggcgtaatca tggctcatagc tgtttcctgt gtgaaattgt tatccgaaca ataggtgtac 1980
taggacttca aggagcagtt agagagcaca tccatgcgat tgaagcatgc ggcgcggctg 2040
gtcttgtcgt aaaacgtccg gagcagctga acgaagtga cgggttgatt ttgccggcg 2100
gtgagagcac gacgatgcgc cgtttgatcg atcgtatca attcatggag ccgcttcgtg 2160
aattcgctgc tcagggcaaa ccgatgtttg gaacatgtgc cggattaatt atattagcaa 2220
aagaaattgc cggttcagat aatcctcatt taggtcttct gaatgtggtt gtagaacgta 2280
attcatttgg ccggcagggt gacagctttg aagctgattt aacaattaaa ggcttggacg 2340
agccttttac tggggtattc atccgtgctc cgcataattt agaagctggt gaaaatggtg 2400
aagttctatc ggagcataat ggtcgtattg tagccgcgaa acaggggcaa ttccttggct 2460
gctcattcca tccggagctg acagaagatc accgagtgac gcagctgttt gttgaaatg 2520
ttgaggaata taagcaaaag gcacttgtat aaaacagttg aggatccggg atcactagt 2580
cggccgcctg caggtcgacc atatgggaga gctcccaacg cgttggatgc atagcttgag 2640
tattctatag tgtcacctaa atagcttggc gtaatcatgg tcatagctgt ttcctgtgtg 2700
aaattgttat ccgctcacia ttccacacaa catacgagcc ggaagcataa agtgtaaagc 2760
ctggggtgcc taatgagtga gctaactcac attaatgctg ttgcgctcac tgcccgttt 2820
ccagtccgga aacctgtcgt gccagctgca ttaatgaatc ggccaacgcg cggggagagg 2880
cggtttgctg attgggcgct cttccgcttc ctgcgtcact gactcgctgc gctcggtcgt 2940
tcggctgcgg cgagcggatc cagctcactc aaaggcggtg atacggttat ccacagaatc 3000
aggggataac gcaggaaaga acatgtgagc aaaaggccag caaaaaggcca ggaaccgtaa 3060
aaaggccgcg ttgctggcgt ttttcgatag gctccgcccc cctgacgagc atcacaaaaa 3120
ccacgctca agtcagaggt ggcgaaaccg gacagacta taaagatacc aggcgtttcc 3180
tcctgggaag tccctcgtgc gctctcctgt tccgacctg ccgcttaccg gatacctgtc 3240
cgcttttctc ccttcgggaa gcgtggcgct ttctcatagc tcacgctgta ggtatctcag 3300

20250709 1507503

ttcggtgtag gtcgttcgct ccaagctggg ctgtgtgcac gaaccccccg ttcagcccca 3360
 ccgctgcgcc ttatccggtg actatcgtct tgagtccaac ccggttaagac acgacttata 3420
 gccactggca gcagccactg gtaacaggat tagcagagcg aggtatgtag gcggtgctac 3480
 agagttcttg aagtggtggc ctaactacgg ctacactaga aggacagtat ttggtatctg 3540
 cgctctgctg aagccagtta ccttcggaaa aagagttggt agctcttgat ccggcaaaaa 3600
 aaccaccgct ggtagcggg gttttttgt ttgcaagcag cagattacgc gcagaaaaaa 3660
 aggatctcaa gaagatcctt tgatcttttc tacggggtct gacgctcagt ggaacgaaaa 3720
 ctacagttaa gggatttttg tcatgagatt atcaaaaagg atcttcacct agatcctttt 3780
 aaattaaaaa tgaagtttta aatcaatcta aagtatatat gagtaacctt ggtctgacag 3840
 ttaccaatgc ttaatcagtg aggcacctat ctacgcgata tgtctatttc gttcatccat 3900
 agttgcctga ctccccgtcg tgtagataac tacgatacgg gagggcttac catctggccc 3960
 cagtgtgcga atgataccgc gagaccacag ctaccggct ccagatttat cagcaataaa 4020
 ccagccagcc ggaaggcccg agcgcagaag tggctctgca actttatccg cctccatcca 4080
 gtctattaat gtgtgccggg aagctagagt aagtagttcg ccagttaata gtttgcgcaa 4140
 cgttgttgga attgctacag gcatcgtggt gtcacgctcg tcgtttggtg tggcttcatt 4200
 cagctccggt tcccaacgat caaggcgagt tacatgatcc cccatgttgt gcaaaaaagc 4260
 ggtagctcc ttcggtcctc cgatcgttgt cagaagtaag ttggccgcag tgttatcact 4320
 catggttatg gcagcactgc ataattctct tactgtcatg ccatccgtaa gatgcttttc 4380
 tgtgactggt gagtactcaa ccaagtcatt ctgagaatac cgcgcccgcc gaccgagttg 4440
 ctcttgcccg gcgtcaatac gggataatag tgtatgacat agcagaactt taaaagtgtc 4500
 catcattgga aaacgttctt cggggcgaaa actctcaagg atcttaccgc tgttgagatc 4560
 cagttcgatg taaccactc gtgcaccaa ctgatcttca gcatctttta ctttcaccag 4620
 cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaagggaa taaggcgac 4680
 acggaatgt tgaatactca tactcttctt ttttcaatat tattgaagca tttatcaggg 4740
 ttattgtctc atgagcggat acatatttga atgtatttag aaaaataaac aaatagggt 4800
 tccgcgcaca tttcccgaa aagtgccacc tgtatgcggt gtgaaatacc gcacagatgc 4860
 gtaaggagaa aataccgcat caggcgaaat tgtaaacggt aatattttgt taaaattcgc 4920
 gttaaatatt tgttaaatac gctcattttt taaccaatag gccgaaatcg gcaaaatccc 4980
 ttataaatca aaagaataga ccgagatagg gttgagtgtt gttccagttt ggaacaagag 5040
 tccactatta aagaacgtgg actccaacgt caaaggcgca aaaaccgtct atcagggcga 5100
 tggcccacta cgtgaacat caccctaatc aagttttttg cggtcagggt gccgtaaacg 5160
 tctaaatcgg aaccctaaag ggagcccccg atttagagct tgacggggaa agccggcgaa 5220
 cgtggcgaga aaggaaggga agaaagcgaa aggagcgggc gctagggcgc tggcaagtgt 5280
 agcggtcacg ctgcgcgtaa ccaccacacc cgccgcgctt aa 5322

<210> 6
 <211> 5297
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> plasmid - pDX11F

<400> 6
 tgcgccgcta cagggcgcgt ccattcgcca ttcaggctgc gcaactgttg ggaagggcga 60
 tcggtgcggg cctcttcgct attacgccag ctggcgaaag ggggatgtgc tgcaaggcga 120
 ttaagtggg taacgccagg gttttccag tcacgacgtt gtaaaacgac ggccagtga 180
 ttgtaatacg actcactata gggcgaaatt ggcccgacgt cgcagtctcc cggccgccat 240
 ggccgcggga tccctctaga ggaggagaca taatggaacg tacaacgaat tttaacgcag 300
 gtctgcagc gctgccactg gaagttctgc aaaaagcaca gaaagaattt attgatttta 360
 acgaatccgg catgtctgtt atggagcttt ccaccgcag caaagagtat gaagcgggtc 420
 accaaaaagc gaaaagcctc ttaatcgaac tgatgggcat tccggaagat tacgatattc 480
 tgtttcttca agcgggggca agccttcaat tctcaatgct tccgatgaac tttttaacac 540
 ctgaaaaaac cgcacatttt gtgatgaccg gcgcttggtc tgaaaaagca ctggcagaaa 600
 cgaaactgtt cgggaacacg tctatcaccg ctacaagtga aacagacaat tacagttata 660
 ttccagaggt tgaccttacg gatgtaaaag acggcgcata tttacatatc acatccaaca 720
 atacaatttt cggaactcag tggcaggagt ttccgaattc tccaattccg ctctagccg 780
 acatgtccag cgatatttta agcagaaaaa tcgatgtgtc caaatttgat gtgatctacg 840
 gaggcacac tagtgccggc gcctgcaggt cgaccatatg ggagaggcgg ccgcgtcgac 900

60367089.032202

2025-03-09 10:36:03

caatagttac ccttattatc aagataagaa agaaaaggat ttttcgctac gctcaaatcc 960
 ttttaaaaaa cacaaaagac cacatTTTTT aatgtggtct ttattcttca actaaagcac 1020
 ccattagttc aacaaacgaa aattggataa agtgggatat ttttaaaata tatatttatg 1080
 ttacagtaat attgactttt aaaaaaggat tgattctaata gaagaaagca gacaagtaag 1140
 cctcctaaat tcacttttaga taaaaattta ggaggcatat caaatgaact ttaataaaaat 1200
 tgatttagac aattggaaga gaaaagagat atttaatcat tatttgaacc aacaaacgac 1260
 ttttagtata accacagaaa ttgatattag tgtttttatac cgaaacataa aacaagaagg 1320
 atataaattt taccctgcat ttattttctt agtgacaagg gtgataaact caaatacagc 1380
 ttttagaact ggttacaata gcgacggaga gttagggtat tgggataagt tagagccact 1440
 ttatacaatt tttgatggtg tatctaaaac attctctggt atttggaact ctgtaaagaa 1500
 tgacttcaaa gagttttatg atttatacct ttctgatgta gagaaatata atgggttcggg 1560
 gaaattgttt cccaaaacac ctatacctga aaatgctttt tctctttcta ttattccatg 1620
 gacttcattt actgggttta acttaaatat caataataat agtaattacc ttctacccat 1680
 tattacagca ggaaaattca ttaataaagg taattcaata tatttaccgc tatctttaca 1740
 ggtacatcat tctgtttgtg atgggttatca tgcaggattg tttatgaact ctattcagga 1800
 attgtcagat aggcctaata actggctttt ataataatgag ataatgccga ctgtactttt 1860
 tacagtcggt tttctaatagt cactaaactg ccccggttagt tgaagaagggt ttttatatta 1920
 cagctccggt accgggctcc caacgcgttg gatgcatagc ttgagtattc tatagtgtca 1980
 cctaaatagc ttggcgtaata catggtcata gctgtttcct gtgtgaaatt gttatccgta 2040
 gtcatcatga aaaaaagctg gctgcaaaat gaaaatgcga acgtcccaaa aatcttgaaa 2100
 tattccacgc atgtcaaagc ggattcactc tacaacactc cgccgacatt tgcgatttat 2160
 atgctgagcc tctgtctgga atggctcaag gaaaacgcgc gtgtggaagc tgttgaacag 2220
 cgcaatgaac aaaaagcgca ggttctctac agctgtattg atgaaagcaa cggtctctat 2280
 aaaggacatg ccagaaaaga cagccgctca cgcatgaatg tcacattcac gcttcgggat 2340
 gacgaattaa cgaaaacatt cgttcagaaa gcaaaagatg cgaagatgat cggccttggc 2400
 ggacaccggt cgggtgggagg ctgccgcgct totatttata acgcggtctc tctcgaagac 2460
 tgtgaaaaat tagctgcgtt catgaagaaa ttccagcagg aaaaatgagta aaaagtctgg 2520
 ctatgcattc cgtccgggat ccgggatcac tagtgccggc gcctgcagggt cgaccatatg 2580
 ggagagctcc caacgcgttg gatgcatagc ttgagtattc tatagtgtca cctaaatagc 2640
 ttggcgtaat catggtcata gctgtttcct gtgtgaaatt gttatccgct cacaattcca 2700
 cacaacatac gagccggaag cataaagtgt aaagcctggg gtgcctaata agtgagctaa 2760
 ctcacattaa ttgcgttgcg ctcaactgcc gctttccagt cgggaaacct gtcgtgccag 2820
 ctgcattaat gaatcgccca acgcgcgggg agagggcggt tgcgtattgg gcgctcttcc 2880
 gcttcctcgc tcaactgactc gctgcgctcg gtcgttcggc tgcggcgagc ggtatcagct 2940
 cactcaaagg cggtaatagc gttatccaca gaatcagggg ataacgcagg aaagaacatg 3000
 tgagcaaaa ggcagcaaaa ggccaggaac cgtaaaaaagg cgcggttgc ggcgttttcc 3060
 gataggctcc gcccccctga cgagcatcac aaaaatcgac gctcaagtca gaggtggcga 3120
 aacccgacag gactataaag ataccaggcg tttccccctg gaagctccct cgtgcgctct 3180
 cctgttccga ccctgccgct taccggatac ctgtccgctt ttctcccttc gggaagcggt 3240
 gcgctttctc atagctcacg ctgtagggtat ctcaagttcg ttaggtcgtt tcgctccaag 3300
 ctgggctgtg tgcacgaacc ccccggtcag cccgaccgct gcgcttatc cggtaactat 3360
 cgtcttgagt ccaaccgggt aagacacgac ttatcgccac tggcagcagc cactggtaac 3420
 aggattagca gagcgaggta tgtaggcggt gctacagagt tcttgaagtg gtggcctaac 3480
 tacggctaca ctagaaggac agtatttgggt atctgcgctc tgcgtgaagc agttaccttc 3540
 ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag cgggtggttt 3600
 tttgtttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc 3660
 ttttctacgg ggtctgacgc tcagtggaac gaaaaactcac gtttaagggt tttggtcatg 3720
 agattatcaa aaagatctt cacctagatc cttttaaatt aaaaatgaag ttttaaatca 3780
 atctaaagta tatatgagta aacttgggtc gacagttacc aatgcttaat cagtgaaggca 3840
 cctatctcag cgatctgtct atttcgttca tccatagtgt cctgactccc cgtcgtgtag 3900
 ataactacga tacgggagggt cttaccatct ggccccagtg ctgcaatgat accgcgagac 3960
 ccacgctcac cggctccaga tttatcagca ataaaccagc cagccggaag ggccgagcgc 4020
 agaagtggtc ctgcaacttt atccgctcc ttaattgttg ccgggaagct 4080
 agagtaagta gttcgccagt taatagtgtg cgcaacggtt ttggcattgc tacaggcatc 4140
 gtggtgtcac gctcgtcgtt tgggtatggt tcattcagct ccggttccca acgatcaagg 4200
 cgagttacat gatccccat gttgtgcaa aaagcggtta gtccttcg tctccgatc 4260
 gttgtcagaa gtaagtggc cgagtggtta tcaactcatg ttatggcagc actgcataat 4320
 tctcttactg tcatgccatc cgtaagatgc ttttctgtga ctggtgagta ctcaaccaag 4380
 tcattctgag aataccgcgc ccggcgaccg agttgctctt gcccgcgctc aatacgggat 4440
 aatagtgtat gacatagcag caatttaaaa gtgctcatca ttgaaaaacg ttcttcgggg 4500
 cgaaaaactct caaggatctt accgctgttg agatccagtt cgatgtaacc cactcgtgca 4560

```

cccaactgat cttcagcatc ttttactttc accagcggtt ctgggtgagc aaaaacagga 4620
aggcaaaaatg ccgcaaaaaa gggaataagg gcgacacgga aatggtgaat actcatactc 4680
ttcctttttc aatattattg aagcatttat cagggttatt gtctcatgag cggatacata 4740
tttgaatgta tttagaaaaa taaacaaata ggggttccgc gcacatttcc ccgaaaagt 4800
ccacctgtat gcggtgtgaa ataccgcaca gatgcgtaag gagaaaaatac cgcacagggc 4860
gaaattgtaa acgttaatat tttgttaaaa ttcgcgttaa atatttgtta aatcagctca 4920
ttttttaacc aataggccga aatcggaaca atcccttata aatcaaaaaga atagaccgag 4980
ataggggttg gtgttgttcc agtttggaac aagagtccac tattaagaa cgtggactcc 5040
aacgtcaaag ggcgaaaaac cgtctatcag ggcgatggcc cactacgtga accatcacc 5100
aaatcaagtt ttttgcggtc gaggtgccgt aaagctctaa atcggaaccc taaagggagc 5160
ccccgattta gagcttgacg gggaaagccg gcgaacgtgg cgagaaagga aggggaagaa 5220
gcgaaaggag cgggcgctag ggcgctggca agtgtagcgg tcacgctgcg cgtaaccacc 5280
acaccgcgcg cgcttaa

```

<210> 7

<211> 6731

<212> DNA

<213> Artificial Sequence

<220>

<223> plasmid - pDX14R

<400> 7

```

ttcgggccgc ttcgaaagct gtaatatataa aaccttcttc aactaacggg gcagggttagt 60
gacattagaa aaccgactgt aaaaagtaca gtcggcatta tctcatatta taaaagccag 120
tcattaggcc tatctgacaa ttcctgaata gagttcataa acaatcctgc atgataacca 180
tcacaaacag aatgatgtac ctgtaaagat agcggtaaat atattgaatt acctttatta 240
atgaattttc ctgctgtaat aatgggtaga aggttaattac tattattatt gatatttaag 300
ttaaacccag taaatgaagt ccattggaata atagaaagag aaaaagcatt ttcagggtata 360
gggtgttttg gaaacaattt ccccgaaacca ttatatctct ctacatcaga aagggtataaa 420
tcataaaact ctttgaagtc attctttaca ggagtccaaa taccagagaa tgtttttagat 480
acaccatcaa aaattgtata aagtggctct aacttatecc aataacctaa ctctccgtcg 540
ctattgtaac cagttctaaa agctgtattt gagtttatca cccttgctac taagaaaaata 600
aatgcagggt aaaatttata tccttcttgt tttatgtttc ggtataaaac actaatatca 660
atttctgtgg ttatactaaa agtcgtttgt tggttcaaat aatgattaaa tatctctttt 720
ctcttccaat tgtctaaatc aattttatta aagttcattt gatatgcctc ctaaaatttt 780
atctaaagtg aatttaggag gcttacttgt ctgctttctt cattagaatc aatccttttt 840
taaaagtcaa tattactgta acataaatat atattttaaa aatatccac tttatccaat 900
tttcgtttgt tgaactaatg ggtgctttag ttgaagaata aagaccacat taaaaaatgt 960
ggctctttgt gtttttttaa aggatttgag cgtagcgaaa aatccttttc tttcttatct 1020
tgataataag ggtaactatt gaattcggtt ccaagagttt gtagaaaagc aaaaaggcca 1080
tccgtcagga tggccttctg cttaatttga tgctggcgag tttatggcgg gcgtcctgct 1140
cgccaccctc cgggcccgtt ctgcgaacg ttcaaatccg ctcccgccgg atttgctcta 1200
ctcaggagag cgttcaccga caaacaacag ataaaacgaa aggccagtc ttcgactga 1260
gcctttcggt ttatttgatg cctggcagtt cctactctc gcattggggag accccacact 1320
accatcggtg ctacggcgtt tcacttctga gttcgcatg ggtcagggtg ggaccaccgc 1380
gctactgcgg ccaggcaaat tctgttttat cgaccgctt ctgcgttctg atttaatctg 1440
tatcaggctg aaaatcttct ctcatccgcc aaaacaggat cctcaactgt tttatacaag 1500
tgccttttgc ttatattcct caaccatttc aacaaacagc tgcgtcactc ggtgatcttc 1560
tgtcagctcc ggatggaatg agcagccaag gaattgccc tgtttcgagg ctacaatacg 1620
accattatgc tccgatagaa cttcaacatt ttcaccagct tctaaaatat gcggagcacg 1680
gatgaatacc ccagtaaaaag gctcgtccaa gcccttaatt gttaaatcag cttcaaagct 1740
gtcaacctgc cggccaaatg aattacgttc tacaaccaca ttcagaagac ctaaatgagg 1800
attatctgaa ccggcaattt cttttgctaa tataattaat ccggcacatg ttccaaacat 1860
cggtttgccc tgagcagcga attcacgaag cggctccatg aattgatacg tatcgatcaa 1920
acggcgcatc gtcgtgctct caccgcccgg caaaatcaac ccgtcaactt cgttcagctg 1980
ctccggagct tttacgacaa gaccagccgc gccgcatgct tcaatcgcat ggatgtgctc 2040
tctaactgct ccttgaagtc ctagtacacc tattgttaac atgtcagcag cgctcctatg 2100
ttcttaccag ccgcgttctt gcatacgtg ttctggaagt aagtttgaga tttcaatccc 2160

```

20220307 09:58:09

60367089-032202

tttcattgca	gtaccaagct	cttttgacaa	ctcagcgatt	aatttgtaat	cagtaaagtg	2220
agttgttgct	tccacaattg	ctttcgcaaa	tttagcaggg	ttgtctgatt	taaaaatacc	2280
agaaccaaca	aatactccgt	cagcaccaag	ctgcatcatg	agagcagcat	cagctggagt	2340
tgctacgccg	ccagcggcaa	agttaacgac	aggaagcttg	ccgtcttttt	taatttgaag	2400
aagaagctcg	taaggagcac	ctagggtttt	cgcttctgtc	attagctcat	cctcaactcat	2460
cgcaactact	ttgcgcactt	gagcggttaac	tttacgcata	tggcgaacag	cctcaacaat	2520
attacctgtt	ccaggtcac	cttttgtgcg	aagcatagaa	gcaccttccg	caatacggcg	2580
ttgtgcttca	ccaagatcac	ggcagccaca	gacaaaagga	actgtgtatt	catttttatt	2640
taaatgaaat	tcttcgtcag	ccggcgctcag	aacttcactt	tcatcaatat	agtcaacacc	2700
catagcttca	agcacacgcg	cttcaacaat	atgtccgata	cgcgcttttg	ccattaccgg	2760
gatagatact	gcattcatta	cttcttccac	gattgtaggg	tcagccatac	gggcaactcc	2820
tccagccgcg	cgaatatctg	ctggcacacg	ttctagcgcc	attacagcga	cagctccagc	2880
ttcttcagcg	attttcgctt	gttccgcatt	gatgacgtcc	atgatgacgc	cgcttttttg	2940
cattttctgcc	attccgcgtt	ttacacgttc	gttacctgtt	tgagccatgt	tttctcctcc	3000
tctagagcgt	cctgctgttg	ttagatttat	tataccacac	ctttagata	aagtcaacaa	3060
ctttttgcaa	aatttttcag	gaatttttagc	agaggttggt	ctggatgtag	aacaaaacat	3120
ctttccgctc	ttgtgctgtt	aggatatctt	tcttggaagc	taggtaggcc	tcgagttatg	3180
gcagttgggt	aaaaggaaac	aaaaagaccg	ttttcacaca	aaacggtctt	tttcgatttc	3240
tttttacagt	cacagccact	tttgcaaaaa	ccggacagct	tcatgcctta	taactgctgt	3300
ttcgttcgac	ctgcaggcat	gcaagcttcg	cgaagcgccg	gccgacgcga	ggctggatgg	3360
ccttcccat	tatgattctt	ctcgcttcg	gcgcatcgg	gatgcccgcg	ttgcaggcca	3420
tgctgtccag	gcaggtagat	gacgaccatc	agggacagct	tcaaggatcg	ctcgcggtc	3480
ttaccagcct	aacttcgatc	actggaccgc	tgatcgtcac	ggcgatttat	gccgcctcgg	3540
cgagcacatg	gaacgggttg	gcatggattg	taggcgccgc	cctatacctt	gtctgcctcc	3600
cgcgcttgcg	tcgcggtgca	tggagccggg	ccacctcgac	ctgaatggaa	gccggcgcca	3660
cctcgctaac	ggattcacca	ctccaagaat	tggagccaat	caattcttgc	ggagaactgt	3720
gaatgcgcaa	accaaccctt	ggcagaacat	atccatcgcg	tccgccatct	ccagcagccg	3780
cacgcggcg	atctcgggca	gcgttggttc	ctggccacgg	gtgcgcatga	tcgtgctcct	3840
gtcgttgagg	acccggttag	gctggcgggg	ttgccttact	ggttagcaga	atgaatcacc	3900
gatacgcgag	cgaacgtgaa	gcgactgctg	ctgcaaaacg	tctgcgacct	gagcaacaac	3960
atgaatggtc	ttcggtttcc	gtgtttcgtg	aagtctggaa	acgcggaagt	cagcgccctg	4020
ccacattatg	ttccggatct	gcatcgcagg	atgctgctgg	ctaccctgtg	gaacacctac	4080
atctgtatta	acgaagcgct	ggcattgacc	ctgagtgatt	tttctctggt	cccgccgcat	4140
ccatacggcc	agttgtttac	cctcacacag	ttccagtaac	cgggcatgtt	catcatcagt	4200
aaccggtatc	gtgagcatcc	tctctcgttt	catcggtatc	attaccccca	tgaacagaaa	4260
ttccccctta	cacggaggca	tcaagtgacc	aaacaggaaa	aaaccgccct	taacatggcc	4320
cgctttatca	ggaagccagac	attaacgtgt	ctggagaaac	tcaacgagct	ggacgcggat	4380
gaacaggcag	acatctgtga	atcgcttcac	gaccacgctg	atgagcttta	ccgcagctgc	4440
ctcgcgctgt	tcggtgatga	cggtgaaaac	ctctgacaca	tgcagctccc	ggagacggtc	4500
acagcttgtc	tgtaagcgga	tgccggggagc	agacaagccc	gtcagggcgc	gtcagcgggt	4560
gttgccgggt	gtcggggcgc	agccatgacc	cagtcacgta	gcgatagcgg	agtgtatact	4620
ggcttaacta	tgccgcatca	gagcagattg	tactgagagt	gcaccatatg	cgggtgtgaa	4680
taccgcacag	atgcgtaagg	agaaaataacc	caatcagcgc	ctcttccgct	tctcgcctca	4740
ctgactcgct	gcgctcggtc	gttcggctgc	ggcgagcggg	atcagctcac	tcaaaaggcg	4800
taatacgggt	atccacagaa	tcaggggata	acgcaggaaa	gaacatgtga	gcaaaaggcc	4860
agcaaaaggc	caggaaccgt	aaaaaggccg	cggtgctggc	gtttttccat	aggctccgcc	4920
cccctgacga	gcatcacaaa	aatcgacgct	caagtacagag	gtggcgaaac	ccgacaggac	4980
tataaagata	ccaggcggtt	ccccctggaa	gctccctcgt	gcgctctcct	gttccgaccc	5040
tgccgcttac	cggataacctg	tccgcttttc	tcccttcggg	aagcgtggcg	ctttctcata	5100
gctcacgctg	taggtatctc	agttcggtgt	aggtcggtcg	ctccaagctg	ggctgtgtgc	5160
acgaaccccc	cgttcagccc	gaccgctgcg	ccttatccgg	taactatcgt	cttgagtcca	5220
accggttaag	acacgactta	tcgccactgg	cagcagccac	tggttaacagg	attagcagag	5280
cgaggtatgt	aggcggtgct	acagagtctc	tgaagtgggt	gcctaactac	ggctacacta	5340
gaaggacagt	atttggtatc	tgcgctcttc	tgaagccagt	taccttcgga	aaaagagttg	5400
gtagctcttg	atccggcaaa	caaaaccaccg	ctggtagcgg	tggttttttt	gtttgcaagc	5460
agcagattac	gcgcagaaaa	aaaggatctc	aagaagatcc	tttgcctttt	tctacggggg	5520
ctgacgctca	gtggaacgaa	aactcacggt	aagggatttt	ggtcatgaga	ttatcaaaaa	5580
ggatcttcac	ctagatcctt	ttaaattaaa	aatgaagttt	taaatcaatc	taaagtatat	5640
atgagtaaac	ttggtctgac	agttaccaat	gcttaatcag	tgaggcacct	atctcagcga	5700
tctgtctatt	tcgttcaccc	atagttgcct	gactccccgt	cgtgtagata	actacgatac	5760
gggagggctt	accatctggc	cccagtgctg	caatgatacc	gcgagaccca	cgctcacccg	5820

```

ctccagattt atcagcaata aaccagccag ccggaagggc cgagcgcaga agtggctcgt 5880
caacttttat cgcctccatc cagtctatta attgttgccg ggaagctaga gtaagtagtt 5940
cgccagttaa tagtttgccg aacgttggtt ccattgctgc aggcacgtg gtgtcacgct 6000
cgctgtttgg tatggcttca ttcagctccg gttcccaacg atcaaggcga gttacatgat 6060
ccccatggt gtgcaaaaaa gcggttagct ccttcggtcc tccgatcggt gtcagaagta 6120
agttggccgc agtggtatca ctcatggtta tggcagcact gcataattct cttactgtca 6180
tgccatccgt aagatgcttt tctgtgactg gtgagtactc aaccaagtca ttctgagaat 6240
agtgtagcgt gcgaccgagt tgccttggcc cggcgtaaat acgggataat accgcgccac 6300
atagcagaac tttaaaagtg ctcatcattg gaaaacgttc ttcggggcga aaactctcaa 6360
ggatcttacc gctgttgaga tccagttcga tgtaaccac tctgtcacc aactgatctt 6420
cagcatcttt tactttcacc agcgtttctg ggtgagcaaa aacagggaagg caaaatgccg 6480
caaaaaaggg aataagggcg acacggaaat gttgaatact catactcttc ctttttcaat 6540
attattgaag catttatcag ggttattgtc tcatgagcgg atacatatat gaatgtatatt 6600
agaaaaataa acaaataggg gttccgcgca catttcccg aaaagtgcc cctgacgtct 6660
aagaaaccat tattatcatg acattaacct ataaaaatag gcgtatcacg aggccctttc 6720
gtcttcaaga a                                     6731

```

<210> 8

<211> 10181

<212> DNA

<213> Artificial Sequence

<220>

<223> plasmid - pDX17R

<400> 8

```

gaattttgcg gccgcttcga aagctgtaat ataaaaacct tcttcaacta acggggcagg 60
ttagtgacat tagaaaaaccg actgtaaaaa gtacagtcgg cattatctca tattataaaa 120
gccagtcatt aggcctatct gacaattcct gaatagagtt cataaacaat cctgcatgat 180
aaccatcaca aacagaatga tgtacctgta aagatagcgg taaatatatt gaattacctt 240
tattaatgaa ttttctgct gtaataatgg gtagaaggta attactatta ttattgatat 300
ttaagttaaa cccagtaaat gaagtccatg gaataataga aagagaaaaa gcattttcag 360
gtataggtgt tttgggaaac aatttccccg aaccattata tttctctaca tcagaaagggt 420
ataaatcata aaactctttg aagtcattct ttacaggagt ccaaatacca gagaatggtt 480
tagatacacc atcaaaaatt gtataaagtg gctctaactt atcccaataa cctaactctc 540
cgctcgctatt gtaaccagtt ctaaaagctg tatttgagtt tatcaccctt gtcactaaga 600
aaataaatgc aggtataaat ttatatcctt cttgttttat gtttcggtat aaaacactaa 660
tatcaatttc tgtggttata ctaaaagtcg tttgttggtt caaataatga ttaaatatct 720
ctttctctct ccaattgtct aaatcaattt tattaagtt catttgatat gcctcctaaa 780
tttttatcta aagtgaattt agggagctta cttgtctgct ttcttcatta gaatcaatcc 840
ttttttaaaa gtcaatatta ctgtaacata atatatatt ttaaaaatat cccactttat 900
ccaattttcg tttgttgaac taatgggtgc tttagttgaa gaataaagac cacattaaaa 960
aatgtggtct tttgtgtttt ttaaaaggat ttgagcgtag cgaaaaatcc ttttctttct 1020
tatcttgata ataagggtaa ctattgaatt cggtaaccaag agtttgtaga aacgcaaaaa 1080
ggccatccgt caggatggcc ttctgcttaa tttgatgcct ggcagtttat ggcgggcgtc 1140
ctgcccgcca ccctccgggc cgttgcttcg caacgttcaa atccgctccc ggcggatttg 1200
tcctactcag gagagcgttc accgacaaac aacagataaa acgaaaggcc cagtctttcg 1260
actgagcctt tctgtttatt tgatgcctgg cagttcccta ctctcgcatg gggagacccc 1320
acactaccat cggcgctacg gcgtttcact tctgagttcg gcaggggtc aggtgggacc 1380
accgcgctac tgccgccagg caaattctgt tttatcagac cgcttctgcg ttctgattta 1440
atctgtatca ggctgaaaat cttctctcat ccgccaaaac aggatcctca actgttttat 1500
acaagtgcct tttgcttata ttctcaacc atttcaacaa acagctgcgt cactcgggtga 1560
tcttctgtca gctccggatg gaatgagcag ccaaggaatt gccctgttt cgcggtaca 1620
atacgaccat tatgctccga tagaacttca acattttcac cagcttctaa aatatgcgga 1680
gcacggatga atacccagat aaaaggctcg tccaagcctt taattgttaa atcagcttca 1740
aagctgtcaa cctgccggcc aaatgaatta cgttctacaa ccacattcag aagacctaaa 1800
tgaggattat ctgaaccggc aatttctttt gctaataata ttaatccggc acatgttcca 1860
aacatcggtt tgccctgagc agcgaattca cgaagcggt ccatgaattg atacgtatcg 1920
atcaaacggc gcacgtcgtt gctctcaccg ccgggcaaaa tcaaccgctc aacttcgttc 1980

```

60367089.032202

60367089.032202

agctgctccg	gacgtttttac	gacaagacca	gccgcgcgcg	atgcttcaat	cgcattgatg	2040
tgctctctaa	ctgctccttg	aagtcctagt	acacctattg	ttaacatgtc	agcagcgctc	2100
ctatgttctt	accagccgcg	ttcttgcata	cgctgttctg	gaagtaagtt	tgagatttca	2160
atccctttca	ttgcagttac	aagctctttt	gacaaactag	cgattaattt	gtaatcagta	2220
aaagttagttg	ttgcttccac	aattgctttc	gcaaatttag	caggggtgtc	tgatttataa	2280
ataccagaac	caacaaatac	tccgtcagca	ccaagctgca	tcattgagagc	agcatcagct	2340
ggagttgcta	cgccgccagc	ggcaaaagta	acgacaggaa	gcttgccgtc	ttttttaatt	2400
tgaaagaagaa	gctcgtaagg	agcacctagg	tttttcgctt	ctgtcattag	ctcatcctca	2460
ctcatcgcaa	ctactttgcg	cacttgagcg	ttacttttac	gcatatggcg	aacagcctca	2520
acaatattac	ctgtttccagg	ctcacctttt	gtgcgaagca	tagaagcacc	ttccgcaata	2580
cggcgtgttg	cttcaccaag	atcacggcag	ccacagacaa	aaggaaactgt	gtattcattt	2640
ttattttaaat	gaaattcttc	gtcagccggc	gtcagaactt	cactttcatc	aatatagtca	2700
acacccttca	cttcacagcac	acgcgcttca	acaatatgtc	cgatacgcgc	ttttgccatt	2760
accgggatag	atactgcatt	cattacttct	tccacgattg	tagggctcagc	catacgggca	2820
actcctccag	ccgcgcgaat	atctgctggc	acacgttcta	gcgccattac	agcgacagct	2880
ccagcttctt	cagcgatttt	cgcttggtcc	gcattgatga	cgtccatgat	gacgccgcct	2940
ttttgcattt	ctgccattcc	gcgtttttaca	cgttcagtag	ctgtttgagc	catgttttct	3000
cctcctctag	aacaggcggg	gttgcccccg	cctgtaatta	aattattaca	caccctgtag	3060
ggaaagtcaa	tacctttttg	taaaattttt	acacagcgtg	gatctcttct	agggacacct	3120
ctttgtaccc	ctcaaggagg	aaatattggc	ggtaactgagc	acagtttttg	ttggtggaca	3180
gtgaaccata	gctgtcgtca	atagcctcga	ggtatggcag	ttggttaaaa	ggaaacaaaa	3240
agaccgtttt	cacacaaaac	ggcttttttc	gatttctttt	tacagtcaca	gccacttttg	3300
caaaaaccgg	acagcttcat	gccttataac	tgctgtttcg	gtcgacgatg	atctgccgtt	3360
ttcttctgca	agccaaaaaa	ccttcggtta	caacgagaag	gattcttcac	tttctaaagt	3420
tcggcgagtt	tcatccctct	gtcccagtc	ttttttggat	caaggcagac	tgctgcaatg	3480
tctatctatt	ttaataatag	gtgcagttcg	caggcgatac	tgccaatgg	aagtatacca	3540
aaatcaacgg	gcttgtagca	acacattagc	ccaattcgat	atcggcagaa	tagatttttt	3600
taatgccttc	gttcgtttct	aaaagcagaa	cgccttcac	atctatacct	aacgccttac	3660
cgtaaaaggt	tccgtttaac	gttctggctc	tcatattagt	gccaataccg	agcgcatagc	3720
tttcccataa	aagcttaatc	ggcgtaaatc	cgtgcgtcat	ataatcccgg	taccgtttct	3780
caaaagcata	taaaatatgc	tggatgacgc	cggcccgatc	aattttttcc	ccagcagcct	3840
ggctgaggtc	tgctgcgatg	tccttcaatt	cattctggaaa	atcattaggc	tgctgggtta	3900
cgtaaatgcc	gatcccaatg	atcaactgaac	gtacgcggtc	ttcttcagcc	tgcatttccg	3960
ttagatatac	gactgttttt	tttccgttaa	tcaaaatata	atttgccat	ttaatatccg	4020
tttgatgcc	tgctgcctct	tctattccct	gcacaacagc	tactgcagca	agcagagtca	4080
gctgcggtg	tttttgagc	ggaatgtcag	gccgcaaaat	caggctcatc	caaacaccgt	4140
ttccttcttg	agaaatgcat	accctagaca	ttcggccctt	tcgggtgtgt	tgtttgtcag	4200
ccaccacaag	ggtgccttcc	ggtgcgttat	tattcgcgag	ctcatgagcc	gttttttgcg	4260
tgcttgaaag	aacgtcatgg	taaaataagat	gctggcccat	cacttccgtt	tttaatccaa	4320
aacgaatttc	gctttcactg	agttttcccg	gttttttgat	gagccgatat	ccttttcttc	4380
taacggcttc	tacttcataa	ccctctttcc	gaagctcttc	aatatgcttc	cacacagcag	4440
ttcttgaaac	gccgagagca	tcactgattt	tttggccgga	aataaattca	ttgccggcct	4500
gagaaaataa	gtcaataagg	tcttttctta	atgttgaccg	catgtcttca	gccactcctc	4560
tatgtgtttc	ttttgattgg	agagcttccc	tgtcacaaca	gcctgctcga	tccactgtaa	4620
ttcttctgac	acctattttc	cggccggccg	gtttcgaagc	gcaagcaagt	ccttaccctg	4680
gatatacaag	tccttaaggc	ttttgatcgg	caggttttga	taagcgtaact	gaatgtcctt	4740
cagtttcttt	tcatccagtt	tttcgttttg	ccgaagctgc	gataattttg	ccgctgagag	4800
cagtgccttt	ttcccagctc	tgtacattgt	cattgcgtca	aggctctggc	caaacgtatc	4860
ggcaatgtga	atggcttcc	tgatcacttt	tcccgggagc	ttccaggctt	tcaggaaaag	4920
gggcgcgtct	ttcaaaaacta	tgccaagggt	aattaaaaga	gcagcccaaa	gctcctcacg	4980
ggatgttaaa	gagaagaatg	gaaactcact	cgttgaaatc	aggttttctc	gtttatgata	5040
aaaaccagga	agctcttcat	acaatctcgt	ttgaatgagt	gtttgaagcg	cctggcgaga	5100
agctcttccc	tgcaagcaat	tctcaaaactc	tatagttttt	cgttcgactg	aaacatggga	5160
gaggagtgat	ttttctttcg	caatggcttc	ttctgtttcc	ggtgaaagcg	taaagccaag	5220
ctggtctcata	aagcgtagcg	ctctcagcat	acgaagcgca	tcctcttgaa	atctatcctc	5280
aggctttcca	acggttcgaa	tcaactttctg	atcaatatct	ttcttgccgc	caaaaataatc	5340
aagcaccttc	ccgtccgctg	tcatggccat	cgcattgatc	gttaaactctc	tgcgtttttag	5400
atcctcttct	aatgatgaga	taaattgcac	ttctgacggt	cttctgaaat	caacataatc	5460
agattcagtc	cggaatgtcg	tgacttcata	ggtttcatcc	tcccagagca	caataatggt	5520
cccgtgctct	ttgcctacat	caacagtcog	ctgaaacagc	cgttctactt	gatcaggtgc	5580
cgcatctgtc	gcgatatcga	catctccgat	cgttcgtttc	atatagctgt	cacgaactgc	5640

60367089 - 032202

```

gcccccgaca aaataagcct gatggccgcg ttcgattaag atgcggagca cgggaagtgc 5700
tttgataaaa acctttttcca tgtgatcact ccgggttctgc taaatcggca taaatctgtt 5760
catactggct gacaattttt ttagaagaaa attcattttc aagcatctct attgccgcct 5820
ttgtaaaacg attgcttagc tgttcactct ctaaaatgct catcgcgcgg gctgttgccg 5880
ccgtaacatc accgacatcc accaaaaatc cgctcacatt gttttttata acctcagggg 5940
taccgccaat gtttgttcca atacaaggca ctccgcaagc catcgcttca agcaggacaa 6000
ggccaaagct ttctttttca gatagcagca gcttcaaatc gctaatagaa taaagatctt 6060
caacacggtc ttgattttcca agcattaaga cttggctctc caagccatat tttctgataa 6120
gctcgcaggc tgtcgatttc tccggaccgt ctccgactaa aagcagcttc gctttcgttt 6180
tgccagcgat attgcggaac acacggatga catcctgcac gcgtgcagcc actggtaaca 6240
ggattagcag agcagggatg tagggcgggt ctacagagtt cttgaagtgg tggcctaact 6300
acgggtacac tagaaggaca gtatttggtg tctgcgctct gctgaagcca gttaccttcg 6360
gaaaaagagt tggtagctct tgatccggca aacaaaccac cgctggtagc ggtgggtttt 6420
ttgtttgcaa gcagcagatt acgcgcagaa aaaaaggatc tcaagaagat cctttgatct 6480
tttctacggg gtctgacgct cagtggaaac aaaactcacg ttaagggatt ttggtcatga 6540
gattatcaaa aaggatcttc acctagatcc ttttaaatta aaaatgaagt tttaaatcaa 6600
tctaaagtat atatgagtaa acttggctctg acagttacca atgcttaatc agtgaggcac 6660
ctatctcagc gatctgtcta tttcgttcat ccatagttgc ctgactcccc gtcgtgtaga 6720
taactacgat acgggagggc ttaccatctg gccccagtgc tgcaatgata ccgcgagacc 6780
cacgctcacc ggctccagat ttatcagcaa taaaccagcc agccggaagg gccgagcgca 6840
gaagtgggtc tgcaacttta tccgcctcca tccagtctat taattgttgc cggaagcta 6900
gagtaagtag ttcgccagtt aatagtttgc gcaacgttgt tgccattgct acaggcatcg 6960
tgggtgcacg ctcgctggtt ggtatggctt cattcagctc cggttcccaa cgatcaaggc 7020
gagttacatg atcccccatg ttgtgcaaaa aagcggtagt ctccctcggg cctccgatcg 7080
ttgtcagaag taagttggcc gcagtgttat cactcatggt tatggcagca ctgcataatt 7140
ctcttactgt catgccatcc gtaagatgct tttctgtgac tggtgagtac tcaaccaagt 7200
cattctgaga atagtgtatg cggcgaccga gttgctcttg cccggcgctc atacgggata 7260
ataccgcgcc acatagcaga actttaaaag tgctcatcat tggaaaaagt tcttcggggc 7320
gaaaaactctc aaggatctta ccgctgttga gatccagttc gatgtaacct actcgtgcac 7380
ccaactgatc ttcagcatct tttactttca ccagcgtttc tgggtgagca aaaacaggaa 7440
ggcaaaaatgc cgcaaaaaag ggaataaggg cgacacggaa atgttgaata ctcatactct 7500
tcctttttca atattattga agcatttatc agggttattg tctcatgagc ggatacatat 7560
ttgaatgtat ttgaaaaaat aaacaaatag gggttccgcg cacatttccc cgaaaagtgc 7620
cacctgacgt ctaagaaacc attattatca tgacattaac ctataaaaaat aggcgtatca 7680
cgaggccctt tcgtctcgca tgcggatcag tgaggggttg caactgcggg tcaaggatct 7740
ggatttcgat cacggcacga tcatcgtagc ggagggcaag ggctccaagg atcgggcctt 7800
gatgttacct gagagcttgg caccagcct gcgcgagcag ggggaattgat ccggtggatg 7860
accttttgaa tgccttttaa tagattatat tactaattaa ttggggagcc tagaggtccc 7920
cttttttatt ttaaaaattt tttcacaaaa cggtttacaa gcataacggg ttttctgcc 7980
cgcaaacggg ctgttctggt gttgctagtt tgttatcaga atcgcagatc cggcttcagg 8040
tttgccggct gaaagcgcta tttcttcagc aattgccatg attttttccc cacgggaggc 8100
gtcactggct cccgtgttgt cggcagcttt gattcgataa gcagcatcgc ctgtttcagg 8160
ctgtctatgt gtgactgttg agctgtaaca agttgtctca ggtgttcaat ttcattgtct 8220
agttgctttg ttttactggt ttcacctggt ctattaggtg ttacatgctg ttcactgttt 8280
acattgtcga tctgttcagc gtgaacagct ttaaattgcac caaaaactcg taaaagctct 8340
gatgtatcta tcttttttac accgttttca tctgtgcata tggacagttt tccctttgat 8400
atctaaccgt gaacagttgt tctacttttg tttgttagtc ttgatgcttc actgatagat 8460
acaagagcca taagaacctc agatccttcc gtatttagcc agtatgttct ctagtgtggt 8520
tcgttgtttt tgcgtgagcc atgagaacga accattgaga tcatgcttac tttgcatgct 8580
actcaaaaat tttgcctcaa aactggtgag ctgaattttt gcagttaaag catcgtgtag 8640
tgtttttctt agtccgttac gtaggtagga atctgatgta atgggtgttg gtattttgtc 8700
accattcatt tttatctggt tgttctcaag ttcggttacg agatccattt gtctatctag 8760
ttcaacttgg aaaatcaacg tatcagtcgg cgggcctcgc ttatcaacca ccaatttcat 8820
attgctgtaa gtgtttaaat ctttacttat tggtttcaaa acccattggt taagcctttt 8880
aaactcatgg tagttatttt caagcattta catgaactta aattcatcaa ggctaactct 8940
tatatttgcc ttgtgagttt tcttttgtgt gatgtctttt aataaccact cataaactct 9000
catagagtat ttgttttcaa aagacttaac atgttccaga ttatatttta tgaatttttt 9060
taactggaaa agataaggca atatctcttc actaaaaact aattctaatt tttcgcttga 9120
gaacttgcca tagtttgtcc actggaaaaat ctcaaagcct ttaaccaaaag gattcctgat 9180
ttccacagtt ctcgatcatc gctctctggt tgcttttagc aatacccat aagcattttc 9240
cctactgatg ttcatcatct gacgctattg gttataagtg aacgataccg tccgttcttt 9300

```



```

ccttgtaggg ttttcaatcg tgggggttgag tagtgccaca cagcataaaa ttagcttgggt 9360
ttcatgctcc gttaagtcac agcgactaat cgctagtcca tttgctttga aaacaactaa 9420
ttcagacata catctcaatt ggtctagggtg attttaatca ctataccaat tgagatgggc 9480
tagtcaatga taattactag tccttttcct ttgagttgtg ggtatctgta aattctgcta 9540
gacctttgct ggaaaacttg taaattctgc tagaccctct gtaaattccg ctagaccttt 9600
gtgtgttttt ttgttttata ttcaagtgggt tataatttat agaataaaga aagaataaaa 9660
aaagataaaa agaataagatc ccagccctgt gtataactca ctactttagt cagttccgca 9720
gtattacaac aggatgtcgc aaacgctgtt tgctcctcta caaacagac cttaaaacc 9780
taagggtta agtagcacc cgcgaagctc gggcaaatcg ctgaatattc cttttgtctc 9840
cgaccatcag gcacctgagt cgctgtcttt ttctgtgacat tcagttcgct gcgctcacgg 9900
ctctggcagt gaatgggggt aaatggcact acaggcgct tttatggatt catgcaagga 9960
aactacccat aatacaagaa aagcccgtca cgggcttctc agggcgtttt atggcggggc 10020
tgctatgtgg tgctatctga ctttttgctg ttcagcagtt cctgccctct gattttccag 10080
tctgaccact tcggattatc cgtgacagg tcattcagac tggctaagtc acccagtaag 10140
gcagcgggtat catcaacagg cttaccctgc ttactgtcaa c 10181

```

```

<210> 9
<211> 194
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> promoter sequence

```

```

<400> 9
gctattgacg acagctatgg ttactgtcc accaaccaaa actgtgtcca gtaccgcca 60
tatttctccc ttgaggggta caaagagggtg tccctagaag agatccacgc tgtgtaaaaa 120
ttttacaaaa aggtattgac tttccctaca ggggtgtgtaa taatttaatt acaggcgggg 180
gcaacccgc ctgt 194

```

```

<210> 10
<211> 163
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> promoter sequence

```

```

<400> 10
gcctacctag cttccaagaa agatattcta acagcacaag agcggaaaga tgttttgttc 60
tacatccaga acaacctctg ctaaaattcc tgaaaaattt tgcaaaaagt tgttgacttt 120
atctacaagg tgtgtgataa taatcttaac aacagcagga cgc 163

```

```

<210> 11
<211> 127
<212> DNA
<213> Artificial Sequence

```

```

<220>
<223> promoter sequence

```

```

<400> 11
gaggaatcat agaattttgt caaaataatt ttattgacaa cgtcttatta acgttgatat 60
aatttaaatt ttatttgaca aaaatgggct cgtgtgtgtac aataaatgta gtgaggtgga 120
tgcaatg 127

```

```

<210> 12
<211> 42
<212> DNA

```

B0367089-032202

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 12

gaaatcatat aactatacct tgattagggg gaccaagaaa tg

42

<210> 13

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 13

caagaacgcg gctggtaaga acataggagc gctgctgaca tg

42

<210> 14

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 14

tctagaaaagg aggtga

16

<210> 15

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 15

tctagaagga ggagaaaaca tg

22

<210> 16

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 16

tctagaggag gagaaaacat g

21

<210> 17

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 17

20220203 09:03:03

taagaacaaa ggaggagagc tgacatg

27

<210> 18

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 18

taagaacaga ggaggagagc tgacatg

27

<210> 19

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> ribosome binding site

<400> 19

taagaagaaa ggaggtagc tgacatg

27

20220708 16:03:00